CA2298451A1 - Secreted proteins and polynucleotides encoding them - Google Patents

Abstract

Novel polynucleotides and the proteins encoded thereby are disclosed.

Description

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
This application is a continuation-in-part of application Ser. No. 60/XXX,XXX
(converted to a provisional application from non-provisional application Ser.
No.
08/906,708), filed August 6,1997, which is incorporated by reference herein.
FI~~LD OF THE IIWEN~ON
The present invention provides novel poiynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
BACKGROUND OF THE INVENTION
Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein 2 0 in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

- ;zZJMNIARY OF THE INVENTION
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) - a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:1 from nucleotide 8b4 to nucleotide 1340;
(c) a poiynucleotide comprising the nucleotide sequence of SEQ ID
NO:1 from nucleotide 1 to nucleotide 1175;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bi127 5 deposited under accession number ATCC 98501;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bi127_5 deposited under accession number ATCC 98501;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bi127_5 deposited under accession number ATCC 98501;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone bi127_5 deposited under accession number ATCC 98501;
2 0 (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:2;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID N0:2;
2 5 (j) a polynucleotide which is an allelic variant of a polynucleotide of (a}-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (1} a polynucleotide that hybridizes under stringent conditions to any 3 0 one of the polynucleotides specified in (a}-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:1 from nucleotide 864 to nucleotide 1340; the nucleotide sequence of SEQ ID
N0:1 from nucleotide 1 to nucleotide 1175; the nucleotide sequence of the full-length protein coding sequence of clone bi127 5 deposited under accession number ATCC 98501;
or the nucleotide sequence of a mature protein coding sequence of clone bi127 5 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone bi127 5 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:2 from amino acid 1 to amino and 104.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID N0:2.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:1.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:2;
2 0 (b) the amino acid sequence of SEQ ID N0:2 from amino acid 1 to amino acid 104;
(c) fragments of the amino acid sequence of SEQ ID N0:2 comprising eight consecutive amino acids of SEQ ID N0:2; and (d) the amino acid sequence encoded by the cDNA insert of clone 2 5 bi127 5 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:2 or the amino acid sequence of SEQ ID N0:2 from amino arid 1 to amino and 104. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid 3 0 sequence of SEQ ID N0:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID N0:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 4b to nucleotide 738;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 346 to nucleotide 738;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:3 from nucleotide 688 to nucleotide 1425;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone b1194_2 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone b1194_2 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone b1194 2 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone b1194 2 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:4;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment 2 5 comprising eight consecutive amino acids of SEQ ID N0:4;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (ar(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and 3 0 - (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:3 from nucleotide 46 to nucleotide 738; the nucleotide sequence of SEQ ID
N0:3 from nucleotide 346 to nucleotide 738; the nucleotide sequence of SEQ ID N0:3 from nucleotide 688 to nucleotide 1425; the nucleotide sequence of the full-length protein coding sequence of clone b1194 2 deposited under accession number ATCC 98501;
or the nucleotide sequence of a mature protein coding sequence of clone b1194 2 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone b1194 2 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino and sequence of SEQ ID N0:4 from amino acid 1 to amino acid 171.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 110 to amino acid 119 of SEQ ID N0:4.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:3.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 0 consisting of:
(a) the amino acid sequence of SEQ ID N0:4;
{b) the amino acid sequence of SEQ ID N0:4 from amino acid 1 to amino acid 171;
{c) fragments of the amino acid sequence of SEQ ID N0:4 comprising 2 5 eight consecutive amino acids of SEQ ID N0:4; and (d) the amino acid sequence encoded by the cDNA insert of clone b1194_2 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:4 or the amino acid sequence 3 0 ~ of SEQ ID N0:4 from amino and 1 to amino acid 171. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:4 *rB

having biological activity, the fragment comprising the amino acid sequence from amino acid 110 to amino acid 119 of SEQ ID N0:4.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 234 to nucleotide 1235;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 291 to nucleotide 1235;
(d) a polynucleoHde comprising the nucleotide sequence of SEQ ID
N0:5 from nucleotide 209 to nucleotide 1050;
(e} a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cc130_1 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cc130_1 deposited under accession number ATCC 98501;
(g} a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cc130_1 deposited under accession number 2 0 ATCC 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cc130_1 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:6;
2 5 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID N0:6;
(k) a polynucleotide which is an allelic variant of a polynucleotide of {a)-(h) above;
3 0 (1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such poiynucleotide comprises the nucleotide sequence of SEQ ID
N0:5 from nucleotide 234 to nucleotide 1235; the nucleotide sequence of SEQ ID
N0:5 from nucleotide 291 to nucleotide 1235; the nucleotide sequence of SEQ ID N0:5 from nucleotide 209 to nucleotide 1050; the nucleotide sequence of the full-length protein coding sequence of clone cc130_1 deposited under accession number ATCC 98501;
or the nucleotide sequence of a mature protein coding sequence of clone cc130_1 deposited under accession number ATCC 98501. In other preferred embodiments, the poiynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone cc130_1 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a poiynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:6 from amino acid 1 to amino acid 272.
In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:6, or a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID N0:6.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:5.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:6;
2 5 (b) the amino acid sequence of SEQ ID N0:6 from amino acid 1 to amino acid 272;
(c) fragments of the amino acid sequence of SEQ ID N0:6 comprising eight consecutive amino acids of SEQ ID N0:6; and (d) the amino acid sequence encoded by the cDNA insert of clone 3 0 ~ cc130_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:6 or the amino acid sequence of SEQ ID N0:6 from amino and 1 to amino acid 272. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID N0:6.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1554 to nucleotide 1784;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1659 to nucleotide 1784;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1508 to nucleotide 1865;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ch582_1 deposited under accession number ATCC 98501;
{f) a polynucleotide encoding the full-length protein encoded by the 2 0 cDNA insert of clone ch582_1 deposited under accession number ATCC 98501;
(g} a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ch582 1 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
2 5 insert of clone ch582_1 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:8;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment 3 0 comprising eight consecutive amino acids of SEQ ID N0:8;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a}-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and *rB

(m) -a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in {a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1554 to nucleotide 1784; the nucleotide sequence of SEQ
ID N0:7 from nucleotide 1659 to nucleotide 1784; the nucleotide sequence of SEQ ID
N0:7 from nucleotide 1508 to nucleotide 1865; the nucleotide sequence of the full-length protein coding sequence of clone ch582 1 deposited under accession number ATCC 98501;
or the nucleotide sequence of a mature protein coding sequence of clone ch582_1 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone ch582 1 deposited under accession number ATCC 98501. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID N0:8.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:7.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:8;
2 5 (b) fragments of the amino acid sequence of SEQ ID N0:8 comprising eight consecutive amino acids of SEQ ID N0:8; and (c) the amino acid sequence encoded by the cDNA insert of clone ch582_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such 3 0 protein comprises the amino acid sequence of SEQ ID N0:8. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID N0:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID N0:8.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 1375 to nucleotide 1605;
(c) a polynudeotide comprising the nucleotide sequence of SEQ ID
N0:9 from nucleotide 1107 to nucleotide 1539;
(d} a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cq294_14 deposited under accession number ATCC 98501;
(e) a polynucleotide encoding the full-length protein encoded by the 2 5 cDNA insert of clone cq294_14 deposited under accession number ATCC 98501;
(f} a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cq294_14 deposited under accession number ATCC 98501;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone cq294_14 deposited under accession number ATCC 98501;
{h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:10;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment 2 5 comprising eight consecutive amino acids of SEQ ID N0:10;
(j) a polynucleotide which is an aDelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and 3 0 - (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:9 from nucleotide 1375 to nucleotide 1605; the nucleotide sequence of SEQ
ID N0:9 from nucleotide 1107 to nucleotide 1539; the nucleotide sequence of the full-length protein *rB

WO 99107840 PCT/US9811b318 coding sequence of clone cq294_14 deposited under accession number ATCC 98501;
or~he nucleotide sequence of a mature protein coding sequence of clone cq294_14 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone cq294_14 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:10 from amino acid 1 to amino acid 55. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID N0:10.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:9.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID NO:10;
(b) the amino acid sequence of SEQ ID N0:10 from amino acid 1 to amino acid 55;
(c) fragments of the amino acid sequence of SEQ ID N0:10 comprising eight consecutive amino acids of SEQ ID NO:10; and 2 5 (d) the amino acid sequence encoded by the cDNA insert of clone cq294_14 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:10 or the amino acid sequence of SEQ ID NO:10 from amino acid 1 to amino and 55. In further preferred embodiments, 3 0 the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 33 to amino acid 42 of SEQ ID N0:10.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11 from nucleotide 66 to nucleotide 1880;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:11 from nucleotide 1 to nucleotide 581;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd454_1 deposited under accession number ATCC 98501;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd454_1 deposited under accession number ATCC 98501;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd454_1 deposited under accession number ATCC 98501;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone dd454_I deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment 2 5 comprising eight consecutive amino acids of SEQ ID N0:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and 3 0 (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:11 from nucleotide 66 to nucleotide 1880; the nucleotide sequence of SEQ ID
N0:11 from nucleotide 1 to nucleotide 581; the nucleotide sequence of the full-length protein coding sequence of clone dd454_1 deposited under accession number ATCC 98501;
or the nucleotide sequence of a mature protein coding sequence of clone dd454_1 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone dd454_1 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:12 from amino acid 1 to amino acid 172. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 297 to amino acid 306 of SEQ ID N0:12.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:11.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:12;
(b) the amino acid sequence of SEQ ID N0:12 from amino acid 1 to amino acid 172;
(c) fragments of the amino acid sequence of SEQ ID N0:12 comprising eight consecutive amino acids of SEQ ID N0:12; and 2 5 (d) the amino acid sequence encoded by the cDNA insert of clone dd454_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:12 or the amino acid sequence of SEQ ID N0:12 from amino acid 1 to amino aad 172. In further preferred embodiments, 3 0 the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:12 having biological activity, the fragment comprising the amino acid sequence from ammo acid 297 to amino acid 306 of SEQ ID N0:12.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:13 from nucleotide 462 to nucleotide 3170;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
2 0 N0:13 from nucleotide 1188 to nucleotide 1517;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone du157 12 deposited under accession number ATCC 98724;
(e} a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone du157 12 deposited under accession number ATCC 98724;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone du157_12 deposited under accession number ATCC 98724;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
2 0 insert of clone du157_12 deposited under accession number ATCC 98724;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:14;
(i} a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment 2 5 comprising eight consecutive amino acids of SEQ ID N0:14;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and 3 0 - (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:13 from nucleotide 462 to nucleotide 3170; the nucleotide sequence of SEQ
ID N0:13 from nucleotide 1188 to nucleotide 1517; the nucleotide sequence of the full-length protein coding sequence of clone du157_12 deposited under accession number ATCC 98724;
or the nucleotide sequence of a mature protein coding sequence of clone du157_12 deposited under accession number ATCC 98724. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone du157_12 deposited under accession number ATCC 98724. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:14 from amino acid 251 to amino acid 352. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:14, or a polynucleotide enrnding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 446 to amino acid 455 of SEQ ID N0:14.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:13.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
2 0 (a) the amino acid sequence of SEQ ID N0:14;
(b) the amino acid sequence of SEQ ID N0:14 from amino acid 251 to amino acid 352;
(c) fragments of the amino acid sequence of SEQ ID N0:14 comprising eight consecutive amino acids of SEQ ID N0:14; and 2 5 (d) the amino acid sequence encoded by the cDNA insert of clone du157_12 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:14 or the amino acid sequence of SEQ ID N0:14 from amino acid 251 to amino acid 352. In further preferred 3 0 ~ embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:14, or a protein comprising a fragment of the amino acid sequence of *rB

SEQ ID N0:14 having biological activity, the fragment comprising the amino acid sequence from amino acid 446 to amino acid 455 of SEQ ID N0:14.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 865 to nucleotide 1158;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 1108 to nucleotide 1158;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:15 from nucleotide 1 to nucleotide 764;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone du372_1 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone du372_1 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone du372 1 deposited under accession number 2 0 ATCC 98501;
(h} a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone du372_1 deposited under accession number ATCC 98501;
(i) a polynudeotide encoding a protein comprising the amino acid sequence of SEQ ID N0:16;
2 5 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID N0:16;
(k) a polynudeotide which is an allelic variant of a polynucleotide of (a)-(h) above;
3 0 ~ {1) a poiynudeotide which encodes a species homologue of the protein of (i) or (~) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQZD
N0:15 from nucleotide 865 to nucleotide 1158; the nucleotide sequence of SEQ
ID N0:15 from nucleotide 1108 to nucleotide 1158; the nucleotide sequence of SEQ ID
N0:15 from nucleotide 1 to nucleotide 764; the nucleotide sequence of the full-length protein coding sequence of clone du372_1 deposited under accession number ATCC 98501; or the nucleotide sequence of a mature protein coding sequence of clone du372_1 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA
insert of clone du372_1 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:16 from amino acid 69 to amino acid 98. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID
NO:I6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:16, or a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment comprising the amino acid sequence from amino.acid 44 to amino acid 53 of SEQ ID N0:16.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
2 0 ID N0:15.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:I6;
2 5 (b) the amino acid sequence of SEQ ID N0:16 from amino acid 69 to amino acid 98;
(c) fragments of the amino acid sequence of SEQ ID N0:16 comprising eight consecutive amino acids of SEQ ID N0:16; and (d) the amino acid sequence encoded by the cDNA insert of clone 3 0 - du372_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:16 or the amino acid sequence of SEQ ID N0:16 from amino acid 69 to amino acid 98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:16, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:16 having biological at~tivity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID N0:16.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 fram nucleotide 32 to nucleotide 586;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 92 to nucleotide 586;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:17 from nucleotide 1 to nucleotide 481;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ej90 5 deposited under accession number ATCC 98501;
{f) a polynucleotide encoding the full-length protein encoded by the 2 0 cDNA insert of clone ej90 5 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ej9a_5 deposited under accession number ATCC
98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
2 5 insert of clone ej90 5 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:18;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment 3 0 comprising eight consecutive amino acids of SEQ ID N0:18;
{k) a polynucleotide which is an allelic variant of a polynucleotide of {a)-(h) above;
(1) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and 1$

(m) - a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:17 from nucleotide 32 to nucleotide 586; the nucleotide sequence of SEQ ID
N0:17 from nucleotide 92 to nucleotide 586; the nucleotide sequence of SEQ ID N0:17 from nucleotide 1 to nucleotide 481; the nucleotide sequence of the full-length protein coding sequence of clone ej90 5 deposited under accession number ATCC 98501; or the nucleotide sequence of a mature protein coding sequence of clone ej90_5 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ej90_5 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:18 from amino acid 1 to amino acid 150. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 87 2 0 to amino acid 9b of SEQ ID N0:18.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:17.
In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group 2 5 consisting of:
(a) the amino acid sequence of SEQ ID N0:18;
(b) the amino acid sequence of SEQ ID N0:18 from amino acid 1 to amino acid 150;
(c) fragments of the amino acid sequence of SEQ ID N0:18 comprising 3 0 eight consecutive amino acids of SEQ ID N0:18; and (d) the amino acid sequence encoded by the cDNA insert of clone ej90_5 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:18 or the amino acid sequence of SEQ ID N0:18 fromamino acid i to amino acid i50. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:18, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:18 having biological activity, the fragment comprising the amino acid sequence from amino acid 87 to amino acid 96 of SEQ ID NOaB.
In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 281 to nucleotide 1786;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
25 N0:19 from nucleotide 332 to nucleotide 1786;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
N0:19 from nucleotide 1 to nucleotide 574;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ic2 6 deposited under accession number 2 0 ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ic2 6 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone i~ 6 deposited under accession number ATCC
2 5 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ic2_6 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:20;
3 0 (j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID N0:20;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(1) - a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID
N0:19 from nucleotide 281 to nucleotide 1786; the nucleotide sequence of SEQ
ID N0:19 from nucleotide 332 to nucleotide 1786; the nucleotide sequence of SEQ ID
N0:19 from nucleotide 1 to nucleotide 574; the nucleotide sequence of the full-length protein coding sequence of clone ic2 6 deposited under accession number ATCC 98501; or the nucleotide sequence of a mature protein coding sequence of clone ic2_6 deposited under accession number ATCC 98501. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ic2_6 deposited under accession number ATCC 98501. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID N0:20 from amino acid 1 to amino acid 98. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID N0:20, or a polynucleotide encoding 2 0 a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment comprising the amino acid sequence from amino aad 246 to amino acid 255 of SEQ ID N0:20.
Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
ID N0:19.
2 5 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID N0:20;
(b) the amino acid sequence of SEQ ID N0:20 from amino acid 1 to 3 0 amino acid 98;
(c) fragments of the amino acid sequence of SEQ ID N0:20 comprising eight consecutive amino acids of SEQ ID N0:20; and (d} the amino acid sequence encoded by the cDNA insert of clone i~ 6 deposited under accession number ATCC 98501;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID N0:20 or the amino acid sequence of SEQ ID N0:20 from amino acid 1 to amino acid 98. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID N0:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID
N0:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID
N0:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 246 to amino acid 255 of SEQ ID N0:20.
In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions.
Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the genes) corresponding to the polynucleotide sequences disclosed herein.
Processes are also provided for producing a protein, which comprise:
(a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and (b) purifying the protein from the culture.
2 0 The protein produced according to such methods is also provided by the present invention.
Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.
2 5 Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable earner.

Figures lA and 1B are schematic representations of the pED6 and pNOTs vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION
ISOLATED PROTEINS AND POLYNUCLEOTIDES
Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.
As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g. , receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.
2 0 done "bi127 5"
A polynucleotide of the present invention has been identified as clone "bi127 5".
bi127 5 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer 2 5 analysis of the amino acid sequence of the encoded protein. bi127 5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "bi127_5 protein").
The nucleotide sequence of bi127_5 as presently determined is reported in SEQ
ID
NO:1. What applicants presently believe to be the proper reading frame and the predicted 3 0 amino acid sequence of the bi127_5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:2.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone bi127 5 should be approximately 2500 bp.

The nucleotide sequence disclosed herein for bi127_5 was searched against t-he GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. bi127 5 demonstrated at least some similarity with sequences identified as AA053840 (zf20c06.s 1 Soares fetal heart NbHH 19W Homo sapiens cDNA
clone 377482 3'), AA334304 (EST38496 Embryo, 9 week Homo sapiens cDNA 5' end similar to similar to H. sapiens hypothetical protein, chromosome 3p21.1 gene sequence (GB:L13435)), AA399397 (zt59fll.rl Soares testis NHT Homo sapiens cDNA clone 726669 5'), AA576692 (nm73a07.s 1 NCI CGAP_Co9 Homo sapiens cDNA clone IMAGE:1073844), H01918 (yj29a07.s1 Homo sapiens cDNA clone 150132 3'), H94897 (yu57h08.s1 Homo Sapiens cDNA clone 2302713'), L13435 (Human chromosome 3p21.1 gene sequence), 885965 (yt66g02.s1 Soares retina N2b4HR Homo Sapiens cDNA
clone 275499 3'), and X95828 (H.sapiens DNA NotI jumping clone J32A032D). Based upon sequence similarity, bi127_5 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts a potential transmembrane domain within the bi127 5 protein sequence centered around amino acid 15 of SEQ ID
N0:2.
Clone "b1194 2"
A polynucleotide of the present invention has been identified as clone "b1194 2".
2 0 b1194 2 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. bI194_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as 2 5 "b1194 2 protein").
The nucleotide sequence of b1194_2 as presently determined is reported in SEQ
ID
N0:3. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the b1194 2 protein corresponding to the foregoing nucleotide -sequence is reported in SEQ iD N0:4. Amino acids 88 to 100 are a predicted leader/signal 3 0 sequence, with the predicted mature amino acid sequence beginning at amino acid 101, or are a transmembrane domain.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone b1194 2 should be approximately 1600 bp.
24.

The nucleotide sequence disclosed herein for b1194 2 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. b1194 2 demonstrated at least some similarity with sequences identified as AA13693I (zn97f05.s1 Stratagene fetal retina 937202 Homo Sapiens cDNA
clone 566145 3'), AA148976 {zn99el0.rl Stratagene colon {#937204) Homo sapiens cDNA clone 566346 5'), AA148977 (zn99e10.s1 Stratagene colon (#937204) Homo Sapiens cDNA clone 566346 3'), AA 196293 (zp92g07.s 1 Stratagene HeLa cell s3 Homo sapiens cDNA clone 627708 3'), AA487754 (ab13e12.r1 Stratagene lung (#937210) Homo sapiens cDNA clone 840718 5'), H01254 {yj27b02.r1 Homo Sapiens cDNA clone 149931 5'), H86324 (ytO5f07.r1 Homo sapiens cDNA clone 223429 5'), N23958 {yx71c02.s1 Homo sapiens cDNA clone 267170 3'), N31859 (yx71c02.r1 Homo sapiens cDNA clone 267170 5'), 801674 (ye76b07.s 1 Homo sapiens cDNA clone 123637 3'), and T78480 (yd68g08.s1 Homo Sapiens cDNA clone 113438 3'). The predicted amino acid sequence disclosed herein for b1194 2 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted b1194_2 protein demonstrated at least some similarity to the sequence identified as (NADH dehydrogenase subunit 2, ND2 [human, brain, Peptide Mitochondria) Partial Mutant, 79 aa] [Homo Sapiens]). Based upon sequence similarity, b1194_2 proteins and each similar protein or peptide may share at least some activity.
]lone "cc130 1"
A polynucleotide of the present invention has been identified as clone "cc130 1 ".
cc130_1 was isolated from a human adult brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was 2 5 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cc134_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cc130_1 protein").
The nucleotide sequence of cc130_1 as presently determined is reported in SEQ
ID
3 0 N0:5. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cc130_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:6. Amino acids 7 to 19 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 20, or are a transmembrane domain.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cc130_1 should be approximately 2500 bp.
The nucleotide sequence disclosed herein for cc130_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cc130_1 demonstrated at least some similarity with sequences identified as T21181 (Human gene signature HUMGS02491 ), T70127 (yc 17d06.r 1 Homo Sapiens cDNA clone 80939 5' similar to SP:BUTY_BOVIN P18892 BUTYROPHILIN
PRECURSOR), T92875 (ye27h03.r1 Homo sapiens cDNA clone 118997 5'), U39576 (Human butyrophilin precursor mRNA, complete cds), U90546 (Human butyrophilin (BTF4) mRNA, complete cds), and W69453 (zd45e02.s 1 Soares fetal heart NbHH

Homo Sapiens cDNA clone 343610 3'). The predicted amino acid sequence disclosed herein for cc130_1 was searched against the GenPept and GeneSeq amino acid sequence 2 5 databases using the BLASTX search protocol. The predicted cc130_1 protein demonstrated at least some similarity to sequences identified as M35551 (BOVBUTBTI_1 Bovine butyrophilin mRNA, complete cds. [Bos taurus]), R71361 (Human truncated MOG), U39576 (butyrophilin precursor [Homo sapiens]), and (butyrophilin [Homo sapiens]). Butyrophilin may function in the secretion of milk-fat 2 0 droplets and may act as a specific membrane-associated receptor for the association of cytoplasmic droplets with the apical plasma membrane. The subcellular location of butyrophilin is that of a Type I membrane protein. Butyrophilin also exhibits tissue specificity, being expressed in mammary tissue and secreted in association with the milk-fat-globule membrane during lactation. Butyrophilin is also homologous to MOG
2 5 (myelinoligo dendrocyte protein) which is used to treat auto-immune diseases. Both butyrophilin and MOG are homologous in the same amino acids to an immunoglobulin variable region; this may indicate the existence of a protein-protein binding (receptor) site.
-Based upon sequence similarity, cc130_1 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional 3 0 potential transmembrane domain within the cc130_1 protein sequence centered around amino acid 255 of SEQ ID N0:6.

done "ch582 -1"
A polynucleotide of the present invention has been identified as clone "ch582_1".
ch582_1 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ch582_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ch582_1 protein").
The nucleotide sequence of ch582_1 as presently determined is reported in SEQ
ID N0:7. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ch582_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:8. Amino acids 23 to 35 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 36, or are a transmembrane domain.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ch582_1 should be approximately 2300 bp.
The nucleotide sequence of ch582_1 indicates that it may contain one or more repetitive elements.
2 0 Clone "cc~94 14"
A polynucleotide of the present invention has been identified as clone "cq294_14".
cq294_14 was isolated from a human adult heart cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer 2 5 analysis of the amino acid sequence of the encoded protein. cq294_14 is a full-length clone, including the entire coding sequence of a secreted protein {also referred to herein as "cq294_14 protein").
The nucleotide sequence of cq294_14 as presently determined is reported in SEQ
ID N0:9. What applicants presently believe to be the proper reading frame and the 3 0 predicted amino acid sequence of the cq294_14 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cq294_14 should be approximately 1850 bp.

The nucleotide sequence disclosed herein for cq294_14 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cq294_14 dernonstrated at least some similarity with sequences identified as AA13~962 (z134c12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA
clone 503830 3'), AA447968 (zv83h 10.s 1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA clone 760291 3'), N47086 (yy85c08.s1 Homo sapiens cDNA clone 280334 3'), 833663 (yh82g06.s1 Homo sapiens cDNA clone 136282 3'), 845544 (yg43g12.s1 Homo Sapiens cDNA clone 35358 3'), 877637 (yi76h09.s1 Homo Sapiens cDNA clone 3'), and W37736 (zc10h10.r1 Soares parathyroid tumor NbHPA Homo sapiens cDNA
clone). Based upon sequence similarity, cq294_14 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the cq294_14 protein sequence, centered around amino acids 15, 25, and 50 of SEQ ID NO:10, respectively. The nucleotide sequence of cq294_14 indicates that it may contain one or more repetitive elements.
Clone "dd454 1"
A polynucleotide of the present invention has been identified as clone "dd454_1".
dd454_1 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,63, or was 2 0 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. dd454_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "dd454_1 protein").
The nucleotide sequence of dd454_1 as presently determined is reported in SEQ
2 5 ID N0:11. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the dd454_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12.
The EcoRi/Notl restriction fragment obtainable from the deposit containing clone -dd454_1 should be approximately 2300 bp.
3 0 The nucleotide sequence disclosed herein for dd454_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. dd454_1 demonstrated at least some similarity with sequences identified as AA393499 (zt73g06.r1 Soares testis NHT Homo sapiens cDNA clone 5') and AA430063 (zw67a12.s1 Soares testis NHT Homo sapiens cDNA clone 781246 3').
Based upon sequence similarity, dd454_1 proteins and each similar protein or peptide may share at least some activity.
Clone "du157 12"
A polynucleotide of the present invention has been identified as clone "du157_l2".
du157 12 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. du157_12 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "du157_12 protein").
The nucleotide sequence of du157_12 as presently determined is reported in SEQ
ID N0:13. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the du157_22 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:14.
The EcoIZI/NotI restriction fragment obtainable from the deposit containing clone du157_12 should be approximately 4050 bp.
The nucleotide sequence disclosed herein for du157_12 was searched against the 2 0 GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. du157 12 demonstrated at least some similarity with sequences identified as AA164862 {zq41g04.r1 Stratagene hNT neuron (#937233) Homo sapiens cDNA clone 632310 5'), AA284379 (zs59a07.r1 NCI_CGAP_GCB 1 Homo Sapiens cDNA
clone IMAGE:701748 S'), and T22493 (Human gene signature HUMGS04104). Based 2 5 upon sequence similarity, du157 12 proteins and each similar protein or peptide may share at least some activity.
Clone "du372 1"
A polynudeotide of the present invention has been identified as clone "du372_1".
3 0 du372_1 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. du372_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "du372_1 protein').
The nucleotide sequence of du372_1 as presently determined is reported in SEQ
ID N0:15. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the du372_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:16. Amino acids 69 to 81 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 82, or are a transmembrane domain.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone du372_1 should be approximately 1500 bp.
The nucleotide sequence disclosed herein for du372_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. du372_1 demonstrated at least some similarity with sequences identified as AA099051 (zn45c07.r 1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA
I5 clone 550380 5'), AA424986 (zw06gOl.r1 Soares NhHMPu S 1 Homo sapiens cDNA
clone 768528 5'), AA480114 (zv41hO5.s1 Soares ovary tumor NbHOT Homo sapiens cDNA
clone 756249 3'), H73153 (yu26el 1.r1 Homo Sapiens cDNA clone 234956 5'), and (yu26f1l.rl Homo Sapiens cDNA clone 234957 5'). Based upon sequence similarity, du372_1 proteins and each similar protein or peptide may share at least some activity.
Clone " '90 5"
A polynucleotide of the present invention has been identified as clone "ej90 5".
ej90 5 was isolated from a human adult placenta cDNA library using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was 2 5 identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. ej90 5 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ej90_5 protein").
The nucleotide sequence of ej90 5 as presently determined is reported in SEQ
ID
3 0 N0:17. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ej90 5 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:18. Amino acids 8 to 20 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 21, or are a transmembrane domain.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ej90 5 should be 8pproximately 850 bp.
The nucleotide sequence disclosed herein for ej90_5 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ej90 5 demonstrated at least some similarity with sequences identified as AA099387 (zk85e10.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA
clone 489642 5'), AA099388 (zk85e10.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 489642 3'), AA256657 (zr85c06.r1 Soares NhHMPu S 1 Homo sapiens cDNA
clone 682474 5'), and X85111 (X.laevis mRNA for XEL-1). Based upon sequence similarity, ej90 5 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts an additional potential trans-membrane domain within the ej90 5 protein sequence centered around amino acid of SEQ ID N0:18.
Clone "ic2 6"
A polynucleotide of the present invention has been identified as clone "ic2 6".
i~ 6 was isolated from a human adult retina (retinoblastoma WERI-Rbl) cDNA
library 2 0 using methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat.
No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein.
ic2 6 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "ic2_6 protein").
2 5 The nucleotide sequence of i~ 6 as presently determined is reported in SEQ
ID
N0:19. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the ic2 6 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID N0:20. Amino acids 5 to 17 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at 3 0 amino acid 18, or are a transmembrane domain.
The EcoRI/NotI restriction fragment obtainable from the deposit containing clone ic2_6 should be approximately 2000 bp.

The nucleotide sequence disclosed herein for i~ 6 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. ic2_6 demonstrated at least some similarity with sequences identified as AA104139 (mp03a12.r1 Stratagene mouse heart (#937316) Mus musculus cDNA clone 568126 5'), N39195 (yv26e08.s1 Homo sapiens cDNA clone 243878 3'), and 259762 (H.sapiens CpG DNA, clone 171h5, reverse read cpg171h5.rtla). Based upon sequence similarity, i~ 6 proteins and each similar protein or peptide may share at least some activity.
2 0 Deposit of Clones Clones bi127 5, b1194_2, cc130_l, ch582_l, cq294_14, dd454_l, du157 9, du372_1, ej90_5, and ic2_6 were deposited on August 5, 1997 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC
98501, from which each clone comprising a particular polynucleotide is obtainable. Clone du157_12 is an additional isolate of clone du157 9 and was deposited on April 7,1998 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and was given the accession number ATCC 98724, from which the du157_12 clone comprising a 2 0 particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. ~ 1.808(b), and the term of the deposit will comply with 37 C.F.R. ~ 1.806.
Each clone has been transfected into separate bacterial cells (E. coli) in this 2 5 composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector - ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate 3 0 cDNA cloning (Kaufman et al.,1991, Nucleic Acids Res.19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman et aL,1989, MoI. CeII. Blot. 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the CIaI site. In some instances, the deposited clone can become "flipped"

(i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.
Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
An oligonudeotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
C_ lone Probe Seauence bi127 5 SEQ ID N0:21 b1194_2 SEQ ID N0:22 cc130_1 SEQ ID N0:23 ch582_1 SEQ ID N0:24 cq294_14 SEQ ID N0:25 2 0 dd454_1 SEQ ID N0:26 du157 12 SEQ ID N0:27 du372_1 SEQ ID N0:28 ej90_5 SEQ ID N0:29 ic2_6 SEQ ID N0:30 In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoaramidite residue rather than a nucleotide (such as , for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-3 0 diisopropyl)-phosphoramadite) (Glen Research, cat. no.10-1953)).
The design of the oligonucleotide probe should preferably follow these parameters:
(a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's'"), if any;

(b) It should be designed to have a T°, of approx. 80 ° C
(assuming 2° for each A or T and 4 degrees for each G or C).
The oligonucleotide should preferably be labeled with g-~P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used.
Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole.
The bacterial culture containing the pool of full-length clones should preferably be thawed and 100111 of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampiciilin at 100 lZg/ml. The culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 pg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.
Standard colony hybridization procedures should then be used to transfer the 2 0 colonies to nitrocellulose filters and lyse, denature and bake them.
The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCI/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS,100 llg/ml of yeast RNA, and 10 mM EDTA
(approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of ZX SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes.
A third wash with O.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The 3 0 filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

*rB

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.
Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et ai., Bio/Technology 1~, 773-778 (1992} and in R.S.
McDowell, et ai., J. Amer. Chem. Soc.114, 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker"
sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.
The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature forms) of such protein may be obtained by expression of the disclosed full-length 2 0 polynucleotide (preferably those deposited with ATCC} in a suitable mammalian cell or other host cell. The sequences) of the mature forms) of the protein may also be determinable from the amino acid sequence of the full-length form.
The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that 2 5 are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can 3 0 be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.
Organisms that have enhanced, reduced, or modified expression of the genes) corresponding to 'the polynucleotide sequences disclosed herein are provided.
The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morns,1994, Trends Pharmacol. Sci.15(7): 250-254; Lavarosky et al.,1997, Biochem. Mol. Med. b2(1):11-22; and Hampel,1998, Prog. Nucleic Acid Res. Mol.
Biol. 58:1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the genes} corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided.
Transgenic animals that have modified genetic control regions that increase ar reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 Bl, incorporated by reference herein).
In addition, organisms are provided in which the genes) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene{s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation 2 0 can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk,1992, Bioessays 14(9): 629-633; Zwaal et al.,1993, Proc. Natl.
Acad. Sci. USA 90(16): 7431-7435; Clark et al.,1994, Proc. Natl. Acad. Sci.
USA 91(2): 719-722;
all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour et al.,1988, 2 5 Nature 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059;
5,631,153; 5,614, 396;
5,616,491; and 5,679,523; all of which are incorporated by reference herein).
These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene{s), and for the development of 3 0 assay systems for the identification of molecules that interact with the protein products) of the corresponding gene(s).
Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides far soluble forms of such protein. In such forms part or all of the intracellular and transmembrane domains of the protein are deleted such that the protein is fully sezreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.
Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90%
or 95%
identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity;
most preferably at least 95% identity) with any such segment of any of the disclosed proteins.
Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence 2 0 identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30%
sequence identity (more preferably, at least 45% identity; most preferably at least 60%
identity} with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when 2 5 aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian - species. Most preferably, species homologues are those isolated from certain mammalian 3 0 species such as, for example, Pan troglodytes, GoriIIa gorilla, Pongo pygmaeus, Hylobates concolor, Macaca mulaffa, Papio papio, Papio hamadryas, Cercopithecus aethiops, Cebus capucinus, Aotus trivirgatus, Sanguinus Oedipus, Microcebus murinus, Mus muscuIus, Rattus norvegicus, Cricetulus griseus, Felis catus, Mustela vison, Canis familinris, Oryctolagus cuniculus, Bos taurus, WO 99!07840 PCT/US98/16318 Ovis aries, Sus scrofa, and Eguus caballus, for which genetic maps have been created allowing the identification of synteruc relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuanez, 1988, Ann. Rev. Genet. 22: 323-351; O'Brien et al., 1993, Nature Genetics 3:103-112; Johansson et al.,1995, Genomics 25: 682-690; Lyons et al.,1997, Nature Genetics 15: 47-56; O'Brien et al.,1997, Trends in Genetics 13(10): 393-399;
Carver and Stubbs, 1997, Genome Research 7:1123-1137; all of which are incorporated by reference herein).
The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurnng alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 6(?% sequence identity (more preferably, at least 75% identity; most preferably at least 90%
identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.
The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.
2 0 The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as 2 5 stringent as, for example, conditions G-L; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

StringencyPolynucleotideHybridHybridization TemperatureWash ConditionHybrid Lengthand Temperature (bp)= Buffers and Buffers A DNA:DNA z 50 65C; lxSSC -or- 65C; 0.3xSSC
- 42C; lxSSC, 50% formamide B DNA:DNA <50 TB"; lxSSC TB*; lxSSC

C DNA:RNA 2 50 67C; lxSSC-or- 67C; 0.3xSSC
45C; lxSSC, 50% formamide D DNA:RNA <50 TD*; lxSSC Tp*; lxSSC

E RNA:RNA Z 50 70C; IxSSC -or- 70C; 0.3xSSC
50C; lxSSC, 50% formamide F RNA:RNA <50 TF*; IxSSC TF*; lxSSC

G DNA:DNA 2 50 65C; 4xSSC -or- 65C; lxSSC
42C; 4xSSC, 50% formamide H DNA:DNA <50 TH*; 4xSSC TH*; 4xSSC

I DNA:RNA Z 50 67C; 4xSSC -or- 67C; lxSSC
45C; 4xSSC, 50% formamide J DNA:RNA <50 T~*; 4xSSC T~"; 4xSSC

K RNA:RNA Z 50 70C; 4xSSC -or- 67C; lxSSC
50C; 4xSSC, 50% formamide L RNA:RNA <50 T~"; 2xSSC T~*; 2xSSC

M DNA:DNA 2 50 50C; 4xSSC -or- 50C; 2xSSC
40C; 6xSSC, 50% formamide N DNA:DNA <50 TN*; 6xSSC TN*; 6xSSC

O DNA:RNA 2 50 55C;4xSSC-or- 55C;2xSSC
42C; 6xSSC, 50% formamide P DNA:RNA <50 TP*; 6xSSC Tp*; 6xSSC

Q RNA:RNA 2 50 60C; 4xSSC -or- 60C; 2xSSC
45C; 6xSSC, 50% formamide 2 R RNA:RNA <50 TR*; 4xSSC TR*; 4xSSC

$: The hybrid length is that anticipated for the hybridized regions) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the 2 5 hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.
': SSPE (lxSSPE is 0.15M NaCI, lOmM NaHiPO" and 1.25mM EDTA, pH 7.4) can be substituted for SSC
(lxSSC is 0.15M NaCI and lSmM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.
3 0 "TB - TR: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T"a of the hybrid, where Tm is determined according to the following equations. For hybrids less than 18 base pairs in length, T°,(°C) = 2(# of A + T bases) + 4(# of G +
C bases). For hybrids between 18 and 49 base pairs in length, Tm(°C) =
81.5 + 16.6(log~~[Na*)) + 0.41(%G+C) (b00/N), where N is the number of bases in the hybrid, and [Na*] is the concentration of sodium ions in the 3 5 hybridization buffer ([Na'] for lxSSC = 0.165 M).

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: A
Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and Current Protocols in Molecular Biology,1995, F.M.
Ausubel et al., eds., John Wiley & Sons, l:nc., sections 2.10 and 6.3-6.4, incorporated herein by reference.
Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60%
sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.
The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al., Nucleic Acids Res.1~, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R.
Kaufman, Methods in Enzymology ~ 537-566 (1990). As defined herein "operably 2 0 linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
A number of types of cells may act as suitable host cells for expression of the 2 5 protein. Mammaliaxt host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Co1o205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.
3 0 Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, KIuyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include Escherichia coli, Bacillus subtiiis, Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., lnvitrogen, San Diego, California, U.S.A. (the MaxBac~ kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment station Bulletin No. 1555 (1987), incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."
The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column 2 0 containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-toyopearl~ or Cibacrom blue Sepharose~; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
2 5 Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and 3 0 ~ InVitrogen, respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope.
One such epitope ("Flag") is commercially available from Kodak (New Haven, CT).
Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify.the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substazttially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."
The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
The protein may also be produced by known conventional chemical synthesis.
Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.
The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally 2 0 provided or deliberately engineered. For example, modifications in the peptide or DNA
sequences can be made by those skilled in the art using known techniques.
Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence.
For example, one or more of the cysteine residues may be deleted or replaced with another 2 5 amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.
Other fragments and derivatives of the sequences of proteins which would be 3 0 ~ expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein. Such modifications are believed to be encompassed by the presentinvention.

USES AND BIOLOGICAL ACTIVITY .
The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).
Research Uses and Utilities The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out"
2 0 known sequences in the process of discovering other novel polynucleotides;
for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA
immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially 2 5 binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris et al.,1993, Cell 75: 791-803 and in Rossi et al.,1997, Proc. Natl. Acad.
Sci. LISA 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify 3 0 -inhibitors of the binding interaction.
The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in wluch the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.
Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.
Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. ICimmel eds.,1987.
Nutritional Uses Polynucleotides and proteins of the present invention can also be used as 2 0 nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or 2 5 capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.
~rtokine and Cell Proliferation/Differentiation ActivitX
A protein of the present invention may exhibit cytokine, cell proliferation (either 3 0 - inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell Lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+), 2E8, RBS, DA1,123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.
The activify of a protein of the invention may, among other means, be measured by the following methods:
Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M.
Kn.lisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986;
Bertagnolli et al., J. Immunol.145:1706-1712, 1990; Bertagnolli et al., Cellular Immunology 133:327-341, 1991; Bertagnolli, et al., j. Immunol. 149:3778-3783,1992; Bowman et al., J.
Immunol.152:1756-1761,1994.
Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in:
Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. j.E.e.a.
Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto. 1994; and Measurement of mouse and human Interferon y, Schreiber, R.D. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 2994.
2 0 Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Marine Interleukin 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in Immunology. j.E.e.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto. 1991; deVries et al., j. Exp. Med. 173:1205-1211, 1991; Moreau et al., Nature 2 5 336:690-692, 1988; Greenberger et al., Proc. Natl. Acad. Sci. U.S.A.
80:2931-2938, 1983;
Measurement of mouse and human interleukin 6 - Nordan, R. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto.1991;
Smith et al., Proc. Natl. Acad. Sci. U.S.A. 83:1857-1861, 1986; Measurement of human Interleukin 11- Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In Current Protocols 3 0 ~ in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.15.1 john Wiley and Sons, Toronto.1991;
Measurement of mouse and human Interleukin 9 - Ciarletta, A., Giannotti, J., Clark, S.C.
and Turner, K.j. In Current Protocols in Immunology. J.E.e.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto. 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in:
Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H.
Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience {Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans);
Weinberger et al., Proc. Natl. Acad. Sci. USA 77:6091-6095, 1980; Weinberger et al., Eur. J.
Immun.

11:405-411,1981; Takai et al., J. Immunol. 137:3494-3500,1986; Takai et al., J. Immunol.
140:508-512, 1988.
Immune Stimulating or Suppressing Act A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.
These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal 2 0 infections, or may result from autoimmune disorders. More specifically, infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesvinases, mycobacteria, Leishrnania spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also 2 5 be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.
Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, 3 0 Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft versus-host disease and autoimmune inflammatory eye disease.
Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for WO 99!07840 PCTIUS98/16318 example, organ transplantation), may also be treatable using a protein of the present invention.
Using the proteins of the invention it may also be possible to immune responses, in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T
cell responses or by inducing specific tolerance in T cells, or both.
Immunosuppression of T cell responses is generally an active, non-antigen specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.
Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as , for example, B7)), e.g., preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue 2 0 transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s} on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a 2 5 monomeric form of a peptide having an activity of another B lymphocyte antigen (eg., B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an 3 0 immunosuppressant. Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen blocking reagents may avoid the necessity of repeated adnvnistration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.
The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al., Science 257:789-792 (1992) and Turka et al., Proc. Natl. Acad.
Sci USA, 89:11102-11105 (1992). In addition, marine models of GVHD (see Paul ed., Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease.
. Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases.
Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms.
Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T
cell 2 0 activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of 2 5 human autoimmune diseases. Examples include marine experimental autoimmune encephalitis, systemic lupus erythmatosis in MRL/Ipr/Ipr mice or NZB, hybrid mice, marine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB
rats, and marine experimental myasthenia gravis (see Paul ed., Fundamental Immunology, Raven Press, New York,1989, pp. 840-856).
3 0 - Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.
Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B
lymphocyte antigens systemically.
Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in viho activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in viuo.
In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells {e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma} transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides.
2 0 For example, tumor cells obtained from a patient can be transfected ex viuo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used 2 5 to target a tumor cell for transfection in vivo.
The presence of the peptide of the present invention having the activity of a B
lymphocyte antigens) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which Lack MHC class I or MHC class II
3 0 ~ molecules, or which fail to reexpress sufficient amounts of MHC class I
or MHC class II
molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class I a chain protein and p2 microglobulin protein or an MHC class II a chain protein and an MHC class II
~i chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.

Expression of the appropriate class I or class II MHC in conjunctiox~ with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T
cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construZt which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E.
Coligan, A.M.
ICruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Herrmann et al., Pros. Natl.
Acad. Sci.
USA 78:2488-2492,1981; Herrmann et al., J. I:mmunol.128:2968-1974,1982; Handa et al., J. Immunol.135:1564-1572,1985; Takai et al., J. Immunol.137:3494-3500,1986;
Takai et al., J. Immunol.140:508-512, 1988; Hemnann et al., Proc. Natl. Acad. Sci. USA
78:2488-2492, 2 0 1981; Hemnann et al., J. lrnmunol. 128:1968-1974, 1982; Handa et al., j.
Immunol.
135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowmanet al., J.
Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988;
Bertagnolli et al., Cellular Immunology 133:327-341,1991; Brown et al., J. lmmunol.153:3079-3092, 1994.
Assays for T-cell-dependent immunoglobulin responses and isotype switching 2 5 (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect ThI/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol.144:3028-3033,1990; and Assays for B cell function: In vitro antibody production, Mond, J.J. and Brunswick, M. In Current Protocols in Immunology.
J.E.e.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto.1994.
3 0 ~ Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation, those described in: Current Protocols in Imiriunology, Ed by J. E. Coligan, A.M. ICruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-lnterscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol.137:$494-3500,1986; 'T-akai et al., J. Immunol.140:508-512, 1988; Bertagnolli et al., J. Immunol.149:3778-3783,1992.
Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatorua et al., Journal of Immunology 154:5071-5079,1995; Porgador et al., Journal of Experimental Medicine 182:255-260,1995;
Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264,1989;
Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640,1990.
Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in:
Darzynkiewicz et al., Cytometry 13:795-808,1992; Gorczyca et al., Leukemia 7:659-670,1993;
Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991;
Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897,1993;
Gorczyca et al., International Journal of Oncology 1:639-648,1992.
Assays for proteins that influence early steps of T-cell commitment and 2 0 development include, without limitation, those descried in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122,1994; Galy et al., Blood 85:2770-2778,1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551,1991.
Hematopoiesis Re~ul,_ating ActivitX
2 5 A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies.
Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, 3 0 thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF
activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression;~n supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either in-vivo or ex-vivo (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.
Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151,1995; Keller et 2 0 al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915,1993.
Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of 2 5 Hematopoietic CeIIs. R.I. Freshney, et a1. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992;
Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, LK. and Briddell, R.A. In Culture of Hematopoietic Cells. RI. Freshney, et aI. eds.
Vol pp. 23-39, Wiley-Liss, Inc., New York, NY.1994; Neben et al., Experimental Hematology 22:353-359, 3 0 ~ 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In Culture of Hematopoietic Cells. R.I. Freshney, et at. eds. Vol pp. l-21, Wiley-Liss, Inc.., New York, NY.1994; Long term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In Culture of Hematopoietic Cells. R.I. Freshney, et a1. eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY.1994; Long term culture initiating cell assay, Sutherland, H.J. In Culture of Henaatopoietic Cells. R.I. Freshney, et al. eds. Vol pp.
139-162, Wiley-L,iss, Inc., New York, NY.1994.
Tissue Growth Activi~~
A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the heating of bone fractures and cartilage damage or defects in humans and other animals.
Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of 2 5 congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.
A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce 2 0 differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.
2 5 Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/Iigament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and 3 0 other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of WO 99/0?840 PCT/US98/16318 congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors ex vivv for return in vivo to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.
The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i.e. for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present 2 0 invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
Proteins of the invention may also be useful to promote better or faster closure of 2 5 non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.
It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) 3 0 and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or Iiver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for tissue generation activity include, without limitation, those described 2 0 in: International Patent Publication No. W095 / 16035 (bone, cartilage, tendon);
International Patent Publication No. W095/05846 (nerve, neuronal);
International Patent Publication No. W091 /07491 (skin, endothelium ).
Assays for wound healing activity include, without limitation, those described in:
Winter, Epidermal Wound He lin~_ pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglstein and Mertz, J.
Invest.
Dermatol 71:382-84 (1978).
Activin/lnhibin Activity A protein of the present invention may also exhibit activin- or inhibin-related 2 0 activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin a family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals 2 5 and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a hefierodimer with other protein subunits of the inhibin-(3 group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary.
See, for example, 3 0 United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
The activity of a protein of the invention may, among other means, be measured by the following methods:

WO 99/07840 PCTI(JS98/16318 Assays for activin/inhibin activity include, without limitation, those described in:
Vale et al., Endocrinology 91:562-572,1972; Ling et al., Nature 321:779-782,1986; Vale et al., Nature 321:776-779,1986; Mason et al., Nature 318:659-663,1985; Forage et al., Proc.
Natl. Acad. Sci. USA 83:3091-3095,1986.
Chemotactic/Chemo ~netir Activit~r A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.
Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population 2 0 of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assays for chemotactic activity (which will identify proteins that induce or prevent 2 5 chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub.
Greene 3 0 Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. J. Clin. Invest. 95:1370-1376,1995; Lind et al.
APMIS 103:140-146,1995; Muller et al Eur. J. Immunol. 25:1744-1748; Gruber et al. J. of lmmunol. 152:5860-5867,1994; Johnston et al. J. of Immunol. 153: 1762-1768,1994.

Hemostatic-and Thrombolvti A~t~~~r~ -A protein of the invention may also exhibit hemostatic or thrombolytic activity.
As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
The activity of a protein of the invention may, among other means, be measured by the following methods:
Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140,1986; Burdick et al., Thrombosis Res. 45:413-419,1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 2988.
Receptor/Ligand Act A protein of the present invention may also demonstrate activity as receptors, receptor Iigands or inhibitors or agonists of receptor/ligand interactions.
Examples of 2 0 such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and 2 5 development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors .of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.
3 0 The activity of a protein of the invention may, among other means, be measured by the following methods:
Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology, Ed by j.E. Coligan, A.M.
ICruisbeek, D.H.
Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience- (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987;
Bierer et al., J. Exp. Med.168:1145-1156, 1988; Rosenstein et al., J. Exp.
Med.169:149-160 1989; Stoltenbo~g et al., j. Immunol. Methods 175:59-68,1994; Stitt et al., CeII 80:661-670, 1995.
Anti-Inflammatory ActivitX
Proteins of the present invention may also exhibit anti-inflammatory activity.
The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or.promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infe~ion (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting 2 0 from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.
Cadherin/Tumor Invasion Sup~rescnr,~cBvitv Cadherins are calcium-dependent adhesion molecules that appear to play major 2 5 roles during development, particularly in defining specific cell types.
Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.
3 0 The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of-this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.
E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.
Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue 2 0 in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.
Additionally, proteins of the present invention with cadherin activity, and 2 5 polynucleotides of the present invention encoding such proteins, can used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherirt antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the 3 0 cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.
Fragments of proteins of the present invention with cadherin activity, preferably a polypeptfde comprising a decapeptide of the cadherin recognition site, and poly-nucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.
Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32}: 18809-18817, 1995;
Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.
Tumor Inhibition Activity In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities.
A protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.
2 0 Other Activities A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, 2 5 weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or caricadic cycles or rhythms;
effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, Lipid, protein, 3 0 carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);
effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including rngnitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects;
promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal-or endocrine activity; in the case of enzymes,-correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis}; immunoglobulin-like activity (such as, for example, the abir'rty to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.
ADMINISTRATION AND DOSING
A protein of the present invention {from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable earner.
Such a composition may also contain (in addition to protein and a earner) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL,-8, IL-9, IL-10, IL-11, IL-12, IL-13, l:Lrl4, IL-15, IFN, TNFO, TNF1, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem 2 0 cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to mininnize side effects. Conversely, protein of the present invention may be included 2 5 in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inBannmatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
A protein of the present invention may be active in multimers (e.g., heterodimers 3 0~ or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
The pharmaceutical composition of the invention may be in the form of a complex of the proteins) of present invention along with protein or peptide antigens.
The protein and/or peptide antigen will deliver a stimulatory signal to both H and T
lymphocytes. B
lymphocytes will respond to antigen through their surface immunoglobulin receptor. T
lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. M~iC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigens) to T lymphocytes. The antigen components could also be supplied as purified MHC peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.
The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable earners, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lameliar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No.
4,501,728; U.S.
2 0 Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.
As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or 2 5 amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.
3 0 In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines WO 99/07840 PG"T/US98/16318 or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.
Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection.
Intravenous administration to the patient is preferred.
When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95%
protein of the present invention, and preferably from about 25 to 90% protein of the present invention.
2 0 When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid 2 5 form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.
When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present 3 0 invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A
preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringei s Injection, or other vehicle as known in the art.
The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone.
Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 Ilg to about 100 mg (preferably about O.lng to about 10 mg, more preferably about 0.1 pg to about 1 mg) of protein of the present invention per kg body weight.
The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient.
It is 2 0 contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration.
Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
Protein of the invention may also be used to immunize animals to obtain 2 5 polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KL,~. Methods for synthesizing such peptides are known in the art, for example, as in 3 0 R.P. Merrifield, J. Amer.Chem.Soc. ~, 2149-2154 (1963); J.L. Krstenansky, et al., FEBS Lett.
211. 20 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.
For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device.
When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
Such matrices may be formed of materials presently in use for other implanted medical 2 0 applications.
The choice of matrix material is based on biocompati'bility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation.
Potential matrices for the compositions may be biodegradable and chemically defined calcium 2 5 sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other 3 0 ~ ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging kom 150 to 800 microns.
In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluroruc acid, sodium alginate, polyethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and polyvinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in 2 0 question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-a and TGF-Vii), and insulin-like growth factor (IGF).
The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to 2 5 humans, are desired patients for such treatment with proteins of the present invention.
The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of 3 0 a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF I (insulin like growth factor I), to the final composition, may also effect WO 9910?840 PCTIUS98/16318 the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.
Polynucieotides of the present invention can also be used for gene therapy.
Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).
Cells may also be cultured ex vivo in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells.
Treated cells can then be introduced in vivo for therapeutic purposes.
Patent and literature references cited herein are incorporated by reference as if fully set forth.

SEQUENCE LISTING
< 110 > Jacobs , Kenneth "Express Maii" mailing label numbee:.~6 P N.~r McCoy, John M . '!ate of Deposit D 6 ~ ,~-~ 199.
LaVallie, Edward R. ~ hereby oertity that ttds paper or tsa is being Racie, Lisa A. ,::epos'rced with the United States PosteJ Servivs Evens , Cheryl '=xpress Mail Post office to Addresses" service Merberg, David !mdsr 37 C.FR.I. f0 on the date indicated 8b0YE
_.nd is addressed to the Commissioner of Patents Treacy, Maurice :nd ademarks, W hi ton, p. C. 20236, Agostino, Michael J.
Steininger II, Robert J. -Genetics Institute, Inc.
<120> SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM
<130> GI6051A
<140>
<141>
<160> 30 <170> PatentIn Ver. 2.0 <210> 1 <211> 2271 <212> DNA
<213> Homo sapiens <400> 1 ggcgagcctt tgaggggaac gacttgtcgg agccctaacc aggggtatct ctgagcctgg 60 tgggatcccc ggagcgtcac atcactttcc gatcacttca aagtgtaagg ggggccctac 120 tgacccttgg aatttagggg ggctacccta ggcggcatcc~acaacagaga gaattccctt 180 ggagagggga ccctggtgct cggctgtccc tctcatccgc gtagaaagtc cctcatctgg 240 gggctcccga actcagccct ctcacattgt ggccggcttt actgaccctc acagacccag 300 gctgggccct cccgatagag gccagccaaa ggttcactca gcctctcttt caaggctggt 360 gtatctctaa atcttagacc ctcctccgtt accgtcagcc aggtgggatg cccacgtttt 420 ggagagaaac cgttctgagg aacccgggcc tctgggtccc agctggctct ccggccccca 480 ggttatgtat tctgggttgg ccacaaacag tggaattcta ggcactcccg ggacagggtg 540 ggactgctgt cctcattcat gcaaccagca aatattcacg gcaccttgtt tgtgccagac 600 agcagaccga ggacacggtt gttaccaaga ccaggctgtt gccttggaag agcccagagc 660 gtgtcaaggg agacagccac atcacgccag aaatacatga cagctggatt agccctggga 720 gagggaggcc cagatgtggg agctcagggg aggtgcagct caacgtggag tttggaggag 780 gctaccttga cctttgaatg ccaagtggga gccagccaga tgaaaggggt taaaaactaa 840 tatttatatg acagaagaaa aagatgtcat tccgtaaagt aaacatcatc atcttggtcc 900 tggctgttgc tctcttctta ctggttttgc accataactt cctcagcttg agcagtttgt 960 taaggaatga ggttacagat tcaggaattg tagggcctca acctatagac tttgtcccaa 1020 atgctctccg acatgcagta gatgggagac aagaggagat tcctgtggtc atcgctgcat 1080 ctgaagacag gcttgggggg gccattgcag ctataaacag cattcagcac aacactcgct 1140 ccaatgtgat tttctacatt gttactctca acaatacagc agaccatctc cggtcctggc 1200 tcaacagtga ttccctgaaa agcatcagat acaaaattgt caattttgac cctaaacttt 1260 tggaaggaaa agtaaaggag gatcctgacc agggggaatc catgaaacct gtgatattct 1320 tgccctttac aatacagcac tgaagccagg acatgcagct gcattttcag aagattgtga 1380 ttcagcctct actaaagttg tcatccgtgg agcaggaaac cagtacaatt acattggcta 1440 tcttgactat aaaaaggaaa gaattcgtaa gctttccatg aaagccagca cttgctcatt 1500 taatcctgga gtttttgttg caaacctgac ggaatggaaa cgacagaata taactaacca 1560 actggaaaaa tggatgaaac tcaatgtaga agagggactg tatagcagaa ccctggctgg 1620 tagcatcaca acacctcctc tgcttatcgt attttatcaa cagcactcta ccatcgatcc 1680 tatgtggaat gtccgccacc ttggttccag tgctggaaaa cgatattcac ctcagtttgt 1740 aaaggctgcc aagttactcc attggaatgg acatttgaag ccatggggaa ggactgcttc 1800 atatactgat gtttgggaaa aatggtatat tccagaccca acaggcaaat tcaacctaat 1860 ccgaagatat accgagatct caaacataaa gtgaaacaga atttgaactg taagcaagca 1920 tttctcagga agtcctggaa gatagcatgc gtgggaagta acagttgcta ggcttcaatg 1980 cctatcggta gcaagccatg gaaaaagatg tgtcagctag gtaaagatga caaactgccc 204 tgtctggcag tcagcttccc agacagacta tagactataa atatgtctcc atctgcctta 2100 ccaagtgttt tcttactaca atgctgaatg actggaaaga agaactgata tggctagttc 2160 agctagctgg tacagataat tcaaaactgc tgttggtttt aattttgtaa cctgtggcct 2220 gatctgtaaa taaaacttac atttttcaat aggaaaaaaa aaaaaaaaaa a 2271 <210> 2 <211> 159 <212> PRT
<213> Homo Sapiens <400> 2 Met Ser Phe Arg Lys Val Asn Ile Ile Ile Leu Val Leu Ala Val Ala Leu Phe Leu Leu Val Leu His His Asn Phe Leu Ser Leu Ser Ser Leu Leu Arg Asn Glu Val Thr Asp Ser Gly Ile Val Gly Pro Gln Pro Ile Asp Phe Val Pro Asn Ala Leu Arg His Ala Val Asp Gly Arg Gln Glu Glu Ile Pro Val Val Ile Ala Ala Ser Glu Asp Arg Leu Gly Gly Ala Ile Ala Ala Ile Asn Ser Ile Gln His Asn Thr Arg Ser Asn Val Ile Phe Tyr Ile Val Thr Leu Asn Asn Thr Ala Asp His Leu Arg Ser Trp Leu Asn Ser Asp Ser Leu Lys Ser Ile Arg Tyr Lys Ile Val Asn Phe Asp Pro Lys Leu Leu Glu Gly Lys Val Lys Glu Asp Pro Asp Gln Gly Glu Ser Met Lys Pro Val Ile Phe Leu Pro Phe Thr Ile Gln His <210> 3 <211> 1425 <212> DNA
<213> Homo Sapiens <400> 3 gccgaccgaa gaggctggac atgacaccag tggcatatca cggccatggg gtctcagcat 60 tccgctgctg ctcgcccctc ctcctgcagg cgaaagcaag aagatgacag ggacggtttg 120 ctggctgaac gagagcagga agaagccatt gctcagttcc catatgtgga attcaccggg 180 agagatagca tcacctgtct cacgtgccag gggacaggct acattccaac agagcaagta 240 aatgagttgg tggctttgat cccacacagt gatcagagat tgcgccctca gcgaactaag 300 caatatgtcc tcctgtccat cctgctttgt ctcctggcat ctggtttggt ggttttcttc 360 ctgtttccgc attcagtcct tgtggatgat gacggcatca aagtggtgaa agtcacattt 420 aataagcaag actcccttgt aattctcacc atcatggcca ccctgaaaat caggaactcc 480 aacttctaca cggtggcagt gaccagcctg tccagccaga ttcagtacat gaacacagtg 540 gtgaatttta ccgggaaggc cgagatggga ggaccgtttt cctatgtgta cttcttctgc 600 acggtacctg agatcctggt gcacaacata gtgatcttca tgcgaacttc agtgaagatt 660 tcatacattg gcctcatgac ccagagctcc ttggagacac atcactatgt ggattgtgga 720 ggaaattcca cagctattta acaactgcta ttggttcttc cacacagcgc ctgtagaaga 780 gagcacagca tatgttccca aggcctgagt tctggaccta cccccacgtg gtgtaagcag 840 aggaggaatt ggttcactta actcccagcaaacatcctcctgccacttag.gaggaaacac900 ctccctatgg taccatttat gtttctcagaaccagcagaatcagtgccta gcctgtgccc960 agcaaatagt tggcactcaa taaagatttgcagaatttaatacagatctt ttcagctgtt1020 cttagggcat tataaatgga aatcataacgtggttctaggttatcaaacc atggagtgat1080 gtggagctag gattgtgagt gacctgcaggccattatcagtgcctcatct gtgcagaagt1140 ggcagcagag agggaccatc caaatacctaagagaaaacagacctagtca ggatatgaat1200 ttgtttcagc tgttcccaaa ggcctgggagctttttgaaaagaaagaaaa aagtgtgttg1260 gctttttttt tttttagaaa gttagaattgtttttaccaagagtctatgt ggggcttgat1320 tcacccttca tccattggct ggaacatggattggggatttgatagaaaaa taaaccctgc1380 ttttgattca aaaaaaaaaa aaaaaaaaaaaaaaaaaaaaaaaaa 1425 <210> 4 <211> 231 <212> PRT

<213> Homo Sapiens <400> 4 Met Gly Ser Gln His Ser Ala Arg Ser Ser Cys Arg Ala Ala Pro Arg Lys Gln Glu Asp Asp Arg Leu Leu Glu Arg Glu Gln Asp Gly Ala Glu Glu Ala Ile Ala Gln Phe Val Glu Thr Gly Arg Asp Pro Tyr Phe Ser Ile Thr Cys Leu Thr Cys Thr Gly Ile Pro Thr Glu Gln Gly Tyr Gln Val Asn Glu Leu Val Ala Pro His Asp Gln Arg Leu Leu Ile Ser Arg Pro Gln Arg Thr Lys Gln Leu Leu Ile Leu Leu Cys Tyr Val Ser Leu Leu Ala Ser Gly Leu Val Phe Leu Pro His Ser Val Val Phe Phe Leu Val Asp Asp Asp Gly Ile Val Lys Thr Phe Asn Lys Lys Val Val Gln Asp Ser Leu Val Ile Leu Met Ala Leu Lys Ile Arg Thr Ile Thr Asn Ser Asn Phe Tyr Thr Val Thr Ser Ser Ser Gln Ile Ala Val Leu Gln Tyr Met Asn Thr Val Val Thr Gly Ala Glu Met Gly Asn Phe Lys Gly Pro Phe Ser Tyr Val Tyr Cys Thr Pro Glu Ile Leu Phe Phe Val Val His Asn Ile Val Ile Phe Thr Ser Lys Ile Ser Tyr Met Arg Val Ile Gly Leu Met Thr Gln Ser Glu Thr His Tyr Val Asp Ser Leu His Cys Gly Gly Asn Ser Thr Ala Ile <210> 5 - .
<211> 1921 <212> DNA
<213> Homo Sapiens <400> 5 cttccaaaga gcgactctta ctgtttctca tggtgagaag acaatatttg ctttctcttt 60 ttcctttctt ccggatgaga ggctaagcca taatagaaag aatggagaat tattgattga 120 ccgtctttat tctgtgggct ctgattctcc aatgggaata ccaagggatg gttttccata 180 ctggaaccca aaggtaaaga cactcaagga cagacatttt tggcagagca tagatgaaaa 240 tggcaagttc cctggctttc cttctgctca actttcatgt ctccctcctc ttggtccagc 300 tgctcactcc ttgctcagct cagttttctg tgcttggacc ctctgggccc atcctggcca 360 tggtgggtga agacgctgat ctgccctgtc acctgttccc gaccatgagt gcagagacca 420 tggagctgaa gtgggtaagt tccagcctaa ggcaggtggt gaatgtgtat gcagatggaa 480 aggaagtgga agacaggcag agtgcaccgt atcgagggag aacttcgatt ctgcgggatg 540 gcatcactgc agggaaggct gctctccgaa tacacaacgt cacagcctct gacagtggaa 600 agtacttgtg ttatttccaa gatggtgact tctatgaaaa agccctggtg gagctgaagg 660 ttgcagcact gggttctaat cttcacgtcg aagtgaaggg ttatgaggat ggagggatcc 720 acctggagtg caggtccacc ggctggtacc cccaacccca aatacagtgg agcaacgcca 780 agggagagaa catcccagct gtggaagcac ctgtggttgc agacggagtg ggcctatatg 840 aagtagcagc atctgtgatc atgaaaggcg gctccgggga gggtgtatcc tgcatcatca 900 gaaattccct cctcggcctg gaaaagacag ccagcatttc catcgcagac cccttcttca 960 ggagcgccca gccctggatc gcagccctgg cagggaccct gcctatcttg ctgctgcttc 1020 tcgccggagc cagttacttc ttgtggagac aacagaagga aataactgct ctgtccagtg 1080 agatagaaag tgagcaagag atgaaagaaa tgggatatgc tgcaacagag cgggaaataa 1140 gcctaagaga gagcctccag gaggaactca agaggaaaaa aatccagtac ttgactcgtg 1200 gagaggagtc ttcgtccgat accaataagt cagcctgatg ctctaatgga aaaatggccc 1260 tcttcaagcc tgcctgattt ttcctgcatg ggaagagcgc acatgtagcc ctgaggttcc 1320 cttcccagga cagctccagg atcgagatca ctgtgagtgg ttgtggagtt aagaccccta 1380 tggactcctt cccagctgat tatcagagcc ttagacccag cactccttgg attggctctg 1440 cagagtgtct tggttgagag aataacgttg cagttcccac agggcatgtg actttgaaag 1500 agactaaagg ccacactcag ttaataatgg ggcacagatg tgttcccacc caacaaatgt 1560 gataagtgat cgtgcagcca gagccagcct tccttcagtc aaggtttcca ggcagagcaa 1620 ataccctaga gattctctgt aatattggta atttggatga aggaagctag aagaattaca 1680 gggatgtttt taatcccact atggactcag tctcctggaa aaggatctgt ccactcctgg 1740 tcattggtgg atgttaaacc catattcctt tcaactgctg cctgctaggg aaaactgctc 1800 ctcattatca tcactattat tgctcaccac tgtatcccct ctactgggca agtgcttgtc 1860 aagttctagt tgttcaataa atttgttaat aatgctgaaa aaaaaaaaaa aaaaaaaaaa 1920 a 1921 <210> 6 <211> 334 <212> PRT
<213> Homo Sapiens <400> 6 Met Lys Met Ala Ser Ser Leu Ala Phe Leu Leu Leu Asn Phe His Val Ser Leu Leu Leu Val Gln Leu Leu Thr Pro Cys Ser Ala Gln Phe Ser Val Leu Gly Pro Ser Gly Pro Ile Leu Ala Met Val Gly Glu Asp Ala Asp Leu Pro Cys His Leu Phe Pro Thr Met Ser Ala Glu Thr Met Glu Leu Lys Trp Val Ser Ser Ser Leu Arg Gln Val Val Asn Val Tyr Ala Asp Gly Lys Glu Val Glu Asp Arg Gln Ser Ala Pro Tyr Arg Gly Arg Thr Ser Ile Leu Arg Asp Gly Ile Thr Ala Gly Lys Ala Ala Leu Arg ' Ile His Asn Val Thr Ala Ser Asp Ser Gly Lys Tyr Leu Cys Tyr Phe Gln Asp Gly Asp Phe Tyr Glu Lys Ala Leu Val Glu Leu Lys Val Ala Ala Leu Gly Ser Asn Leu His Val Glu Val Lys Gly Tyr Glu Asp Gly Gly Ile His Leu Glu Cys Arg Ser Thr Gly Trp Tyr Pro Gln Pro Gln Ile Gln Trp Ser Asn Ala Lys Gly Glu Asn Ile Pro Ala Val Glu Ala Pro Val Val Ala Asp Gly Val Gly Leu Tyr Glu Val Ala Ala Ser Val Ile Met Lys Gly Gly Ser Gly Glu Gly Val Ser Cys Ile Ile Arg Asn Ser Leu Leu Gly Leu Glu Lys Thr Ala Ser Ile Ser Ile Ala Asp Pro Phe Phe Arg Ser Ala Gln Pro Trp Ile Ala Ala Leu Ala Gly Thr Leu Pro Ile Leu Leu Leu Leu Leu Ala Gly Ala Ser Tyr Phe Leu Trp Arg Gln Gln Lys Glu Ile Thr Ala Leu Ser Ser Glu Ile Glu Ser Glu Gln Glu Met Lys Glu Met Gly Tyr Ala Ala Thr Glu Arg Glu Ile Ser Leu Arg Glu Ser Leu Gln Glu Glu Leu Lys Arg Lys Lys Ile Gln Tyr Leu Thr Arg Gly Glu Glu Ser Ser Ser Asp Thr Asn Lys Ser Ala <210> 7 <211> 1865 <212> DNA .
<213> Homo Sapiens <400> 7 aatggttcca gccttaatgg agaagccagt ttcttttttc ttgttgtttt attgttttta 60 agcctctctc tggttttcag tagagtttga ccttaaatat catctttgat tactattggt 120 gtccttgtag ttaaggtctt tgcaaaagtt tgagtgcaag ttttaagcta aaaacacgtt 180 tttaaacttt cacaaatttt gtaagatgac aatagcattc tgtaacatag acattatggt 240 aatagtgatt ttctctccat ccctattttg tccagcgatt tccaagttat aagacgtgaa 300 taagactaac cgctcacttc caccagcagc tgacctggtg ggcttttgag ttcaaagagt 360 catttcttca tcttacctcc agcactgcag ggccgtgtga ccttgcagag ccttgtttct 420 cattgatgaa aggagctcat gcctcatgaa gccactggta agggccatgg agctcacggg 480 ccatcaagct tccttcccat cacttgtggg tggaattgac attacccgat gagctcttcc 540 tggggtcacc tgggagggag tggcccatgg gtggtatgac aaaatctcat agtcagtctt 600 tgcagttttc tccacaggta aaatgagatt ttggaaaatt ttcatttgtt tgtatttgtc 660 ccaaggtgag tcttacatat tttgagcaac aaaacgaaga tcattatgaa.aatgtcctta 72(~
tggaagcact ctagggccat tgctcatttt tatgagtcct cgtgctaagt ccctgagtac 780 tgtggctcat gtcttagctg gctaaatcac agtcaaaatt ctcttcttaa gcctcaaaat 840 aagctgctga ttatactgcc tgttggccag actaatcaaa tacatttgat gttttagctg 900 actccagata cttttccttc ctcctccttg gttctttaac tgtcatccca gatctgcgac 960 atgcaataag gaaaa_ctgag tcagggagga agtaggattc cttttgctgc taggaaccac 1020 gttagctttg gattgtccat agaatgcacc cttaacagtt cttggaaaat ggatgatatt 1080 tggttcctgc cccatgttca gtgttctttg gcagctgcaa agcatatcct agctagaatc 1140 cttatcgtct tgaagttcat caaagatttt gaacagtcat ggtggagata caacctaagt 1200 acattcatgc ccattgagac aatcctttgg tttgagcgac ggaaggagga ataaacacat 1260 gaatgtattt tattgaatcc cagagaccct gaaacaccaa gactcattaa tatatgcata 1320 catggatggc agaataataa acctcacctg acctgtcagt gtactctcag tttttaaggt 1380 tctcccaaaa cagggaaact gaaaaatact tgggcagaaa gaaaatatca tcaaataaca 1440 cctatttctt ttcagctata gagatggctg gatatcaaaa gcaccacggg agctttgcaa 1500 tttgctgctc ttttcagccc tcagcttgac tctcagtttt caagagggag aaaatgaatg 1560 tttcccagca ttctctgtcc tttgctccaa agaagagagc aggtgttggc ttccaaacct 1620 tccgtatttt cttattgctg ttagggggat caactgcatg tttcctgagg gaaaagggtg 1680 gctcactgac ctacttgaag gcattctctc agtggaagct gggcaagaga atccagggat 1740 ttcttttgca ggtttctgcg cagtgcccct gccatcaagc tgcctaaaat gtgaatattg 1800 cttccctgcg tttcagaggt ggtaatattg gggcaagtgg tggaggatct aaaaaaaaaa 1860 aaaaa 1865 <210> 8 <211> 77 <212> PRT
<213> Homo sapiens <400> 8 Met Asn Val Ser Gln His Ser Leu Ser Phe Ala Pro Lys Lys Arg Ala Gly Val Gly Phe Gln Thr Phe Arg Ile Phe Leu Leu Leu Leu Gly Gly Ser Thr Ala Cys Phe Leu Arg Glu Lys Gly Gly Ser Leu Thr Tyr Leu Lys Ala Phe Ser Gln Trp Lys Leu Gly Lys Arg Ile Gln Gly Phe Leu Leu Gln Val Ser Ala Gln Cys Pro Cys His Gln Ala Ala <210> 9 <211> 2094 <212> DNA
<213> Homo Sapiens <400> 9 tatgtatttg acagcatggt ataatgaaaa gagcagttgg accagaaggt aaattctagt 60 ccagattttg acatttagat gtgtatatat gggaaagttt cttaaaactt cgagttaatt 120 tttctcatct gtgaaataaa gggattggac tagatactct ttaatagata ttccttatat 180 gcttgtctcc ttctaggtct aaaattctga tcctttagta gtttataaat gattattggt 240 ~tcattttca tcattttagg agctcttttt taaaaaatta ttattatttt ttttgctctg 300 tagcccattt ctagaacatc ttgggagttc taattatgtt ttagataaca taaaaagcat 360 agaatcagac atagttaagc aagaatttca cttagttccc tagtttttac agtctaaata 420 catttttctt tctttaaaac tggaggttac tgataccacc attttcgtca ccaacagcct 480 aataattcac aaagctattt gctaattttt gacacttttt tctttgccag taccattaag 540 ggatttgaat ttttttgagg ttccatgttt atttctttag ttatgagtat gaccttggac 600 aagttacttc tctgtacctg taaagtgaga gtaaaataac atctagttca tagggttgtt 660 gactagtacc tggcccatgg taatcactgt gtcatgttgg ctgttactac cctttaacat 720 gatttgctcc cctccctgtg gtaaaaagta ttcattggca ctactaatta atctgttagc 780 tcaacatata ctaacca~aaa tggaaatttg ttttgtgaaa tacaattgtc_agttcctttt 84~
cattataaga aacgttagtt tattagtagt atatacccct gagaaagcac taatttattt 900 tgaaattgag tggattaatt cataatatga aagctgagaa tgtagattgt cttctttctc 960 tattttgaat agttcataga ataatttatt tcttttatct gggaacaaaa ataactggtc 1020 taatttgtga cattctcaaa catattttac aagtttagat aagttgagaa tggcaaaaac 1080 cacaattact tttgcaacaa tctaatactt ttagaagaaa aatctatctt accttatttt 1140 atactaaaaa aaaaaaaaaa ggccaaagag gcctacagga ttttgagatg gaggaacaca 1200 tatttaattc ccctttatgc cttggttctt gctcctcttt ccacgttgga taacaatttt 1260 ttggttgttt tgtttaagtt ggtgctctga agcttaatct cagtaccctt tactctgaat 1320 tgtcaaattt tgataaaacg tgccattttc tttggtaaga gaaagcaggt cttaatgtct 1380 gccagaacac aatttatatg ccttattggc ttcattaaac ttttagaaaa ctttagcatt 1440 tgttactttt ttccattgca tttactttca aatgcaccta atgaattcgt cacccagtcg 1500 caacttttcc cttctctgtc ccattgcttt ctcctttccc cgacgcacag aataaacatg 1560 aagctcagca gtagaagcgt aatgatttcc ctcaggaaaa acttctgaca gctaggtttt 1620 tcaagggttt ccctgtgcta gctgagatgc aaaacaaatc atggaagatt gcatacctgt 1680 gtggtatttt aaaaacaagt tgactttttc agtttcttga acggttaagg gtggatttaa 1740 aaactagaca gtttagtttt ggggaacaga agctctcttc gtcttaagcc agattctctg 1800 attcttttag acgtcatagc tccttagttc tgctcctgtc gccctaactt ggcatgggca 1860 agttgaagtt catccttaga ctgcagcgtt ctgagcatgg ctgaagtatt aaaatgttta 1920 atatttttta gagcaaaatt gatggaaagc atttggctga atctaaagac ctgcagtcag 1980 attcttcaat gtggtttacc caactggagt agtgataaac accttaatca taaaatgaat 2040 aaaaacaaaa aaaccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa 2094 <210> 10 <211> 77 <212> PRT
<213> Homo Sapiens <400> 20 Met Ser Ala Arg Thr Gln Phe Ile Cys Leu Ile Gly Phe Ile Lys Leu Leu Glu Asn Phe Ser Ile Cys Tyr Phe Phe Pro Leu His Leu Leu Ser Asn Ala Pro Asn Glu Phe Val Thr Gln Ser Gln Leu Phe Pro Ser Leu Ser His Cys Phe Leu Leu Ser Pro Thr His Arg Ile Asn Met Lys Leu so 55 so Ser Ser Arg Ser Val Met Ile Ser Leu Arg Lys Asn Phe <210> 11 <211> 2069 <212> DNA
<213> Homo sapiens <400> 11 aaattcaaca taaacccaaa tctgtacttc tccagaggag cagctctgag gtagaaatta 60 caacgatgaa aagagcacaa cgtacaaaac caagaaagag tctgttgtgt gaagggtcat 120 tcgatgaaga agcttctgca cagtcctttc aggaagtgtt aagtcaatgg agaaccggaa 180 'atcatgatga caacaagaaa cagaatttac atgcagcagt aaaagactca ttggaagaat 240 gcgaagtaca gactaatctg aaaatttgga gagaaccact taatattgaa cttaaagaag 300 acattctatc ctatatggaa aaattatggc ttaaaaaaca caggagaact ccacaagagc 360 aactttttaa aatgctacca gatacgttcc cacatccaca tgaaaccact ggtgatgcac 420 agtgttctca aaatgaaaac gatgaagata gtgatggtga ggagaccaaa gtacaacaca 480 cagctctttt attgccagta gaaacattaa acatagagag acctgaacca tctctaaaga 540 tagtcgaact ggatgatact tatgaagagg aatttgaaga agcagaaaat attgtgcctt 600 acaaagttaa attagctgat gcagacagtc aacgaagttg tgcttttcat gattgtcaga 660 agaatagctt tccatatgaa aatggcatcc atcaacatca tgttttcgat aagggaaaga 720 WO 99/07840 PCTlUS98/16318 gagacttctt aaatctttgt ctgagaaaca gctatactta ttataaagat.aattcaaaag 780 cagaaacttc aaacacagat tttgacaaca tcgtggatcc tgatgtgtat tcttctgaca 840 ttgaaaaaat tgaggaaagc acctcctttg aaagaaattt aaaggagaaa aatataggtt 900 tagaaagtaa tcaaaagtct gatgattcct gtgtatcact tgaaagcaag gacactttgc 960 taggtagaga tttagaaaaa gctcccattg aggagaaatt atctcaagac atcaaagaat 1020 ccttggaatt gagcaatctg tataagaggc caagctttga agaatcaaaa actacaaagt 1080 catcactgtt gttacaagaa atagcctgca gaagtaagcc tataacaaaa caatatcaag 1140 gacttgagag attctttatt tttgatacaa atgaaagact caacttactt ccttctcatc 1200 gtttagaatg caacaattcc agtactagga ttacacttgc agaagacaga gaatggattc 1260 cagaccatag cttaagtgaa tatgctgata atgcaattgt cttgggtgtt ctgcagggtg 1320 ctcagagtcc atcatcaagt agaaaacagc aaaagatggg tcagaaatca cagagacctt 1380 caacagcaaa ttttccactt tccaactctg ttaaagaaag ctccagttgc ctttcatcct 1440 ctcatcctcg atcaagaagt gcagctgctc aatcatcatc tagagctgct tctgaaattt 1500 cagaaattga atatattgat attactgacc agaatgagct ttccttagat gacactactg 1560 atcaacatac tttagacaat ttggaaaaag aattacaagt gctgagatct cttgcagata 1620 cttcagaaaa gctttacagc ttaacctcag aagagttccc agatttcagc agccaatcac 1680 tgaatataag tcagatttcc acagatttcc ttaagacctc acatgtgagg ggtccctgtg 1740 gagttgagga attgagctgt tctggaagag ataccaaaat tcagtctttg ctgtcacttt 1800 ctgagagcag tacagatgag gaggaggaag attttctcaa caagcaacat gtcatcacac 1860 taccgtggtc aaagagtact taaagattat ttgttcatta ctgtttccat tttgtaccca 1920 gagtaaagca aacaactgag aaaagtaacc aagtgattac ctatccaagt gctggagatt 1980 ttgattacta atgtctttga tgtttcaagg ctacaaacta ataaaagtaa aattataagt 2040 tcaaaaaaaa aaaaaaaaaa aaaaaaaaa 2069 <210> 12 <211> 605 <212> PRT
<213> Homo sapiens <400> 12 Met Lys Arg Ala Gln Arg Thr Lys Pro Arg Lys Ser Leu Leu Cys Glu Gly Ser Phe Asp Glu Glu Ala Ser Ala Gln Ser Phe Gln Glu Val Leu Ser Gln Trp Arg Thr Gly Asn His Asp Asp Asn Lys Lys Gln Asn Leu His Ala Ala Val Lys Asp Ser Leu Glu Glu Cys Glu Val Gln Thr Asn Leu Lys Ile Trp Arg Glu Pro Leu Asn Ile Glu Leu Lys Glu Asp Ile Leu Ser Tyr Met Glu Lys Leu Trp Leu Lys Lys His Arg Arg Thr Pro Gln Glu Gln Leu Phe Lys Met Leu Pro Asp Thr Phe Pro His Pro His Glu Thr Thr Gly Asp Ala Gln Cys Ser Gln Asn Glu Asn Asp Glu Asp Ser Asp Gly Glu Glu Thr Lys Val Gln His Thr Ala Leu Leu Leu Pro Val Glu Thr Leu Asn Ile Glu Arg Pro Glu Pro Ser Leu Lys Ile Val Glu Leu Asp Asp Thr Tyr Glu Glu Glu Phe Glu Glu Ala Glu Asn Ile *rB

Val Pro Tyr Lys Val Lys Leu Ala Asp Ala Asp Ser Gln Arg Ser Cys Ala Phe His Asp Cys Gln Lys Asn Ser Phe Pro Tyr Glu Asn Gly Ile His Gln His His Val Phe Asp Lys Gly Lys Arg Asp Phe Leu Asn Leu Cys Leu Arg Asn Ser Tyr Thr Tyr Tyr Lys Asp Asn Ser Lys Ala Glu Thr Ser Asn Thr Asp Phe Asp Asn Ile Val Asp Pro Asp Val Tyr Ser Ser Asp Ile Glu Lys Ile Glu Glu Ser Thr Ser Phe Glu Arg Asn Leu Lys Glu Lys Asn Ile Gly Leu Glu Ser Asn Gln Lys Ser Asp Asp Ser Cys Val Ser Leu Glu Ser Lys Asp Thr Leu Leu Gly Arg Asp Leu Glu Lys Ala Pro Ile Glu Glu Lys Leu Ser Gln Asp Ile Lys Glu Ser Leu Glu Leu Ser Asn Leu Tyr Lys Arg Pro Ser Phe Glu Glu Ser Lys Thr Thr Lys Ser Ser Leu Leu Leu Gln Glu Ile Ala Cys Arg Ser Lys Pro Ile Thr Lys Gln Tyr Gln Gly Leu Glu Arg Phe Phe Ile Phe Asp Thr Asn Glu Arg Leu Asn Leu Leu Pro Ser His Arg Leu Glu Cys Asn Asn Ser Ser Thr Arg Ile Thr Leu Ala Glu Asp Arg Glu Trp Ile Pro Asp His Ser Leu Ser Glu Tyr Ala Asp Asn Ala Ile Val Leu Gly Val Leu Gln Gly Ala Gln Ser Pro Ser Ser Ser Arg Lys Gln Gln Lys Met Gly Gln Lys Ser Gln Arg Pro Ser Thr Ala Asn Phe Pro Leu Ser Asn Ser Val Lys Glu Ser Ser Ser Cys Leu Ser Ser Ser His Pro Arg Ser Arg Ser Ala Ala Ala Gln Ser Ser Ser Arg Ala Ala Ser Glu Ile Ser Glu Ile Glu Tyr Ile Asp Ile Thr Asp Gln Asn Glu Leu Ser Leu Asp Asp ,, Thr Thr Asp Gln His Thr Leu Asp Asn Leu Glu Lys Glu Leu Gln Val Leu Arg Ser Leu Ala Asp Thr Ser Glu Lys Leu Tyr Ser Leu Thr Ser Glu Glu Phe Pro Asp Phe Ser Ser Gln Ser Leu Asn Ile Ser Gln Ile Ser Thr Asp Phe Leu Lys Thr Ser His Val Arg Gly Pro Cys Gly Val Glu Glu Leu Ser Cys Ser Gly Arg Asp Thr Lys Ile Gln Ser Leu~Leu Ser Leu Ser Glu Ser Ser Thr Asp Glu Glu Glu Glu Asp Phe Leu Asn Lys Gln His Val Ile Thr Leu Pro Trp Ser Lys Ser Thr <210> 13 <211> 4337 <212> DNA
<213> Homo Sapiens <400> 13 gtcctggatg gcggagcctt gggttccggg ggcctgggac ctgcaactct ttctacaaga 60 tatcaagtta ttctagtaca accatataaa taaataatac ctgaagtctc agtgtaacat 120 ggacaattaa cagtgatgac agataaatac agacgcatgg ggatcaaata ctaggcaaaa 180 cgctttttaa aagtgtatca ggcttttaag aaacactgca ggatcctgtc tatcttaatg 240 ctgatagagc tcagctaaaa atttaggagg ttctagtatt cttcatggct gaagctgaga 300 gagtctgaaa ccctgatgct taagctccat tctagatcat agctccaact ccttcaggat 360 ataaggaaaa gagattatat ttccacaatg atagatcttt ggttgtacag gtttcccaat 420 gagtggatca tgatgaccgt attgtaggga cttgccatag tatggctgct tcccgatcta 480 ctcgtgttac magatcaaca gtggggttaa acggcttgga tgaatctttt tgtggtagaa 540 ctttaaggaa tcgtagcatt gcgcatcctg aagaaatctc ttctaattct caagtacgat 600 caagatcacc aaagaagaga ccagagcctg tgccaattca gaaaggaaat aataatggga 660 gaaccactga tttaaaacag cagagtaccc gagaatcatg ggtaagccct aggaaaagag 720 gactttcttc ttcagaaaag gataacatag aaaggcaggc tatagaaaat tgtgagagaa 780 ggcaaacaga acctgtttca ccagttttaa aaagaattaa gcgttgtctt agatctgaag 840 caccaaacag ttcagaagaa gattctccta taaaatcaga caaggagtca gtagaacaga 900 ggagtacagt agtggacaat gatgcagatt ttcaagggac taaacgagct tgtcgatgtc 960 ttatactgga tgattgtgag aaaagggaaa ttaaaaaggt gaatgtcagt gaggaagggc 1020 cacttaattc tgcagtagtt gaagaaatca caggctattt ggctgtcaat ggtgttgatg 1080 acagtgattc agctgttata aactgtgatg actgtcagcc tgatgggaac actaaacaaa 1140 atagcattgg ttcctatgtg ttacaggaaa aatcagtagc tgaaaatggg gatacggata 1200 cccaaacttc aatgttcctt gatagtagga aggaggacag ttatatagac cataaggtgc 1260 cttgcacaga ttcacaagtg caggtcaagt tggaggacca caaaatagta actgcctgct 1320 tgcctgtgga acatgttaat cagctgacta ctgagccagc tacagggccc ttttctgaaa 1380 ctcagtcatc tttaagggat tctgaggagg aagtagatgt ggtgggagat agcagtgcct 1440 caaaagagca gtgtaaagaa aacaccaata acgaactgga cacaagtctt gagagtatgc 1500 cagcctccgg agaacctgaa ccatctcctg ttctagactg tgtatcagct caaatgatgt 1560 ctttatcaga acctcaagaa catcgttata ctctgagaac ctcaccacga agggcagccc 1620 ctaccagagg tagtcccact aaaaacagtt ctccttacag agaaaatgga caatttgagg 1680 agaataatct tagtcctaat gaaacaaatg caactgttag tgataatgta agtcaatctc 1740 Ctacaaatcc tggtgaaatt tctcaaaatg aaaaagggat atgttgtgac tctcaaaata 1800 atggaagtga aggagtaagt aaaccaccct cagaggcaag actcaatatt ggacatttgc 1860 catctgccaa agagagtgcc agtcagcaca ttacagaaga ggaagatgat gatcctgatg 1920 tttattactt tgaatcagat catgtggcac tgaaacacaa caaagattat cagagactat 1980 tacagacgat tgctgtactc gaggctcagc gttctcaagc agtccaagac cttgaaagtt 2040 taggcaggca ccagagagaa gcactgaaaa atcccattgg atttgtggaa aaactccaga 2100 agaaggctga tattgggctt ccatatccac agagagttgt tcaattgcct gagatcgtat 2160 gggaccaata tacccatagc cttgggaatt ttgaaagaga atttaaaaat cgtaaaagac 2220 atactagaag agttaagcta gtttttgata aagtaggttt acctgctaga ccaaaaagtc 2280 ctttagatcc taagaaggat ggagagtccc tttcatattc tatgttgcct ttgagtgatg 234Q
gtccagaagg ctcaagcagt cgtcctcaga tgataagagg acgcttgtgt gatgatacca 2400 aacctgaaac atttaaccag ttgtggactg ttgaagaaca gaaaaagctg gaacagctac 2460 tcatcaaata ccctcctgaa gaagtagaat ctcgacgctg gcagaagata gcagatgaat 2520 tgggcaacag gacagcaaaa caggttgcca gccgagtaca gaagtatttc ataaagctaa 2580 ctaaagctgg cattccagta ccaggcagaa caccaaactt atatatatac tccaaaaagt 2640 cttcaacaag cagacgacag caccctctta ataagcatct ctttaagcct tccactttca 2700 tgacttcaca tgaaccgcca gtgtatatgg atgaagatga tgaccgatct tgttttcata 2760 gccacatgaa cactgctgtt gaagatgcat cagatgacga aagtattcct atcatgtata 2820 ggaatttacc tgaatataaa gaactattac agtttaaaaa gttaaagaag cagaaacttc 2880 agcaaatgca agctgaaagt ggatttgtgc aacatgtggg ctttaagtgt gataactgtg 2940 gcatagaacc catccagggt gttcggtggc attgccagga ttgtcctcca gaaatgtctt 3000 tggatttctg tgattcttgt tcagactgtc tacatgaaac agatattcac aaggaagatc 3060 accaattaga acctatttat aggtcagaga cattcttaga cagagactac tgtgtgtctc 3120 agggcaccag ttacaattac cttgacccaa actactttcc agcaaacaga tgacatggaa 3180 gagaacatca tttactagtc ctcttcaaca catagcaatg gtatcattgt taattatgtg 3240 cacagtttgg aaagattctc tgctttccca gaaatgacac tcacagcatg agagcttcct 3300 gagtgttctc gtcaagtaca gctctgcacc gttgtggctc tagatcactg ttcagcagct 3360 gaacattcct ggtgagcaaa ggtttccctg gtgaattttt caccactgcg ttttaggtgg 3420 tgatcttaaa tgggtgagat ggaacgagag cacacattaa agagagagta aattccaaag 3480 gtttcaaaga acttggtcat aaatatgata atgagaagac aaagtattta tattaaaaca 3540 gtttagtagc cttcagtttt gtgaaaatag ttttcagcac agaaactgac ttctttagac 3600 aaagttttaa ccaatgatgg tgtttgcttc taggatatac actttaaaag aactcactgt 3660 cccagtggtg gtcattgatg gcctttagta aattggagct gcttaatcat attgatatct 3720 aatttctttt aaccacaatg aattgtcctt aattaccaac agtgaagcac tacaggaggc 3780 aactgtggca ttgcttcctt aaccagctca tggtgtgtga atgttataaa attgtcactc 3840 agatatattt tttaaatgta atgttatata agatgatcat gtgatgtgta caaactatgg 3900 tgaaaagtgc cagtggtagt aactgtgtaa agtttctaat tcacaacatt aattccttta 3960 aaatacacag ccttctgcct ctgtatttgg agttgtcagt acaactcatc aaagaaaact 4020 gcctaatata aaaatcatat atatggtaat aatttccctc ttttgtagtc tgcacaagat 4080 ccataaaaga ttgtattttt attactattt aaacaagtga ttaaatttag tctgcacagt 4140 gagcaagggt tcacatgcat tcttttatac tgctggattt tgttgtgcat catttaaaac 4200 attttgtatg tttcttctta tctgtgtata cagtatgttc ttgaatgatg ttcatttgtc 4260 aggagaactg tgagaaataa actatgtgga tactgtctgt ttmtrtcaaa aaaaaaaaaa 4320 aaaaaaaaaa aaaaaaa 4337 <210> 14 <211> 903 <212> PRT
<213> Homo sapiens <400> 14 Met Ala Ala Ser Arg Ser Thr Arg Val Thr Arg Ser Thr Val Gly Leu Asn Gly Leu Asp Glu Ser Phe Cys Gly Arg Thr Leu Arg Asn Arg Ser Ile Ala His Pro Glu Glu Ile Ser Ser Asn Ser Gln Val Arg Ser Arg Ser Pro Lys Lys Arg Pro Glu Pro Val Pro Ile Gln Lys Gly Asn Asn Asn Gly Arg Thr Thr Asp Leu Lys Gln Gln Ser Thr Arg Glu Ser Trp Val Ser Pro Arg Lys Arg Gly Leu Ser Ser Ser Glu Lys Asp Asn Ile Glu Arg Gln Ala Ile Glu Asn Cys Glu Arg Arg Gln Thr Glu Pro Val Ser Pro Val Leu Lys Arg Ile Lys Arg Cys Leu Arg Ser Glu Ala Pro Asn Ser Ser Glu Glu Asp Ser Pro Ile Lys Ser Asp Lys Glu Ser Val Glu Gln Arg Ser Thr Val Val Asp Asn Asp Ala Asp Phe Gln Gly Thr Lys Arg Ala Cys Arg Cys Leu Ile Leu Asp Asp Cys Glu Lys Arg Glu Ile Lys Lys Val Asn Val Ser Glu Glu Gly Pro Leu Asn Ser Ala Val Val Glu Glu Ile Thr Gly Tyr Leu Ala Val Asn Gly Val Asp Asp Ser lg5 200 205 Asp Ser Ala Val Ile Asn Cys Asp Asp Cys Gln Pro Asp Gly Asn Thr Lys Gln Asn Ser Ile Gly Ser Tyr Val Leu Gln Glu Lys Ser Val Ala Glu Asn Gly Asp Thr Asp Thr Gln Thr Ser Met Phe Leu Asp Ser Arg Lys Glu Asp Ser Tyr Ile Asp His Lys Val Pro Cys Thr Asp Ser Gln Val Gln Val Lys Leu Glu Asp His Lys Ile Val Thr Ala Cys Leu Pro Val Glu His Val Asn Gln Leu Thr Thr Glu Pro Ala Thr Gly Pro Phe Ser Glu Thr Gln Ser Ser Leu Arg Asp Ser Glu Glu Glu Val Asp Val Val Gly Asp Ser Ser Ala Ser Lys Glu Gln Cys Lys Glu Asn Thr Asn Asn Glu Leu Asp Thr Ser Leu Glu Ser Met Pro Ala Ser Gly Glu Pro Glu Pro Ser Pro Val Leu Asp Cys Val Ser Ala Gln Met Met Ser Leu Ser Glu Pro Gln Glu His Arg Tyr Thr Leu Arg Thr Ser Pro Arg Arg Ala Ala Pro Thr Arg Gly Ser Pro Thr Lys Asn Ser Ser Pro Tyr Arg Glu Asn Gly Gln Phe Glu Glu Asn Asn Leu Ser Pro Asn Glu Thr Asn Ala Thr Val Ser Asp Asn Val Ser Gln Ser Pro Thr Asn Pro Gly Glu Ile Ser Gln Asn Glu Lys Gly Ile Cys Cys Asp Ser Gln Asn Asn Gly Ser Glu Gly Val Ser Lys Pro Pro Ser Glu Ala Arg Leu Asrk Ile Gly His Leu Pro Ser Ala Lys Glu Ser Ala Ser Gln His Ile Thr Glu Glu Glu Asp Asp Asp Pro Asp Val Tyr Tyr Phe Glu Ser Asp His Val Ala Leu Lys His Asn Lys Asp Tyr Gln Arg Leu Leu Gln Thr Ile Ala Val Leu Glu Ala Gln Arg Ser Gln Ala Val Gln Asp Leu Glu Ser Leu Gly Arg His Gln Arg Glu Ala Leu Lys Asn Pro Ile Gly Phe Val Glu Lys Leu Gln Lys Lys Ala Asp Ile Gly Leu Pro Tyr Pro Gln Arg Val Val Gln Leu Pro Glu Ile Val Trp Asp Gln Tyr Thr His Ser Leu Gly Asn Phe Glu Arg Glu Phe Lys Asn Arg Lys Arg His Thr Arg Arg Val Lys Leu Val Phe Asp Lys Val Gly Leu Pro Ala Arg Pro Lys Ser Pro Leu Asp Pro Lys Lys Asp Gly Glu Ser Leu Ser Tyr Ser Met Leu Pro Leu Ser Asp Gly Pro Glu Gly Ser Ser Ser Arg Pro Gln Met Ile Arg Gly Arg Leu Cys Asp Asp Thr Lys Pro Glu Thr Phe Asn Gln Leu Trp Thr Val Glu Glu Gln Lys Lys Leu Glu Gln Leu Leu Ile Lys Tyr Pro Pro Glu Glu Val Glu Ser Arg Arg Trp Gln Lys Ile Ala Asp Glu Leu Gly Asn Arg Thr Ala Lys Gln Val Ala Ser Arg Val Gln Lys Tyr Phe Ile Lys Leu Thr Lys Ala Gly Ile Pro Val Pro Gly Arg Thr Pro Asn Leu Tyr Ile Tyr Ser Lys Lys Ser Ser Thr Ser Arg Arg Gln His Pro Leu Asn Lys His Leu Phe.Lys Pro Ser Thr Phe Met Thr Ser His Glu Pro Pro Val Tyr Met Asp Glu Asp Asp Asp Arg Ser Cys Phe His Ser His Met Asn Thr Ala Val Glu Asp Ala Ser Asp Asp Glu Ser Ile Pro Ile ?70 775 780 WO 99!07840 PCT/US98/16318 Met Tyr Arg Asn Leu Pro Glu Tyr Lys Glu Leu Leu Gln Phe Lys Lys Leu Lys Lys Gln Lys Leu Gln Gln Met Gln Ala Glu Ser Gly Phe Val Gln His Val Gly~Phe Lys Cys Asp Asn Cys Gly Ile Glu Pro Ile Gln Gly Val Arg Trp His Cys Gln Asp Cys Pro Pro Glu Met Ser Leu Asp Phe Cys Asp Ser Cys Ser Asp Cys Leu His Glu Thr Asp Ile His Lys Glu Asp His Gln Leu Glu Pro Ile Tyr Arg Ser Glu Thr Phe Leu Asp Arg Asp Tyr Cys Val Ser Gln Gly Thr Ser Tyr Asn Tyr Leu Asp Pro Asn Tyr Phe Pro Ala Asn Arg <210> 15 <211> 1299 <212> DNA
<213> Homo Sapiens <400> 15 aatcgggacc ccatccccca aatcactgga tcctgcagcc ccacatccta aggtggatcc 60 cacgcttccc tgtgccccct actggatcct ggacctctac gtcttaacca ctggatccca 120 cacaaatcag tgaatggatc ccaacacccc aaccacagga gcacggattc cctgtacctc 180 aacacccaga ccctgcctcc ctcaggcacc agatccagtg tcctagtgaa acgctggatc 240 ctagatcccc aaccccagat ccccatgcct cgagccctgg atctccaagc tcagctgctg 300 gattctggat gtcaacaaac ctcaccactg gatcctgaca accacaatgc ctggatcctg 360 gggcccccat cactggatcc cagatcccct cactccaccc actggattcc tgcattggtt 420 tttggttttt tgtttttttt ttaacctcga cactgggtct cagatccttc tgctgactgc 480 cagatccctg catttcaagc actacgcctt ccacccccag gcactggatc ccagattccc 540 aagccttcac ccaccagatt ctggctccta aaacaagtgc gggggcccca gtggcacagc 600 aagtggatcc tggcaactgc agctgctgga ttccagattc tgggtcccca atccctctgc 660 ccagtccctc aatgttgaaa cctcatctct tgaaggcaga tcctgatatt ccaaggcact ?20 gaatcccaag ccctgaatcc ccggtttctg atctgaatct tccaggcgcc gggtcccaaa 780 tgttcaggcc ccaagtctag atcctggcag cccagtcaca gagtatccca cacacactgg 840 tgcccagagc cggcttctca tgacatgaaa ttgcatggtc gagggagtct gtggggaagg 900 aagcccaggt cctggctgca acctgcacgg atgctggatt ccccctcacc ccacctctgc 960 atggccaccc cctcccagcc ctgtggggaa actgttccct ggaaccactc cactccctgc 1020 atccccacac ttcacagcat cttccatccc cctcccactt ctaggcgaat agtccccaga 1080 gctgtgttcc tccaaggggt ccgaggaatc actcactcct ggaggctggc aaggagacag 1140 tctgaggcca gggacacatg aagggatgtc cccaccccag cactatcagg gcctccccag 1200 gcttccagag ttgaaagcca ggagaaaatc ggcaaagacc acccttccct aaacccaagc 1260 acccaatgat gcraaaaaaa aaaaaaaaaa aaaaaaaaa 1299 z210> 16 <211> 98 <212> PRT
<213> Homo Sapiens <400> 16 Met Lys Leu His Gly Arg Gly Ser Leu Trp Gly Arg Lys Pro Arg Ser *rB

Trp Leu Gln Pro Ala Arg Met Leu Asp Ser Pro Ser Pro His Leu Cys Met Ala Thr Pro Ser Gln Pro Cys Gly Glu Thr Val Pro Trp Asn His Ser Thr Pro Cys Ile Pro Thr Leu His Ser Ile Phe His Pro Pro Pro Thr Ser Arg Arg Ile Val Pro Arg Ala Val Phe Leu Gln Gly Val Arg Gly Ile Thr His Ser Trp Arg Leu Ala Arg Arg Gln Ser Glu Ala Arg Asp Thr <210> 17 <211> 791 <212> DNA
<213> Homo sapiens <400> 17 ctcctctgtc cactgctttc gtgaagacaa gatgaagttc acaattgtct ttgctggact 60 tcttggagtc tttctagctc ctgccctagc taactataat atcaacgtca atgatgacaa 220 caacaatgct ggaagtgggc agcagtcagt gagtgtcaac aatgaacaca atgtggccaa 180 tgttgacaat aacaacggat gggactcctg gaattccatc tgggattatg gaaatggctt 240 tgctgcaacc agactctttc aaaagaagac atgcattgtg cacaaaatga acaaggaagt 300 catgccctcc attcaatccc ttgatgcact ggtcaaggaa aagaagcttc agggtaaggg 360 accaggagga ccacctccca agggcctgat gtactcagtc aacccaaaca aagtcgatga 420 cctgagcaag ttcggaaaaa acattgcaaa catgtgtcgt gggattccaa catacatggc 480 tgaggagatg caagaggcaa gcctgttttt ttactcagga acgtgctaca cgaccagtgt 540 actatggatt gtggacattt ccttctgtgg agacacggtg gagaactaaa caatttttta 600 aagccactat ggatttagtc atctgaatat gctgtgcaga aaaaatatgg gctccagtgg 660 tttttaccat gtcattctga aatttttctc tactagttat gtttgatttc tttaagtttc 720 aataaaatca tttagccttg aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 780 aaaaaaaaaa a 791 <210> 18 <211> 185 <212> PRT
<213> Homo Sapiens <400> 18 Met Lys Phe Thr Ile Val Phe Ala Gly Leu Leu Gly Val Phe Leu Ala Pro Ala Leu Ala Asn Tyr Asn Ile Asn Val Asn Asp Asp Asn Asn Asn Ala Gly Ser Gly Gln Gln Ser Val Ser Val Asn Asn Glu His Asn Val Ala Asn Val Asp Asn Asn Asn Gly Trp Asp Ser Trp Asn Ser Lle Trp Asp Tyr Gly Asn Gly Phe Ala Ala Thr Arg Leu Phe Gln Lys Lys Thr Cys Ile Val His Lys Met Asn Lys Glu Val Met Pro Ser Ile Gln Ser WO 99/07840 PCf/US98/16318 Leu Asp Ala Leu Val Lys Glu Lys Lys Leu Gln Gly Lys Gly Pro Gly Gly Pro Pro Pro Lys Gly Leu Met Tyr Ser Val Asn Pro Asn Lys Val Asp Asp Leu Ser Lys Phe Gly Lys Asn Ile Ala Asn Met Cys Arg Gly Ile Pro Thr Tyr Met Ala Glu Glu Met Gln Glu Ala Ser Leu Phe Phe Tyr Ser Gly Thr Cys Tyr Thr Thr Ser Val Leu Trp Ile Val Asp Ile Ser Phe Cys Gly Asp Thr Val Glu Asn <210> 19 <211> 2012 <212> DNA
<213> Homo sapiens <400> 19 ctcaagttca tcattgtcct gagagagagg agcagcgcgg ttctcggccg ggacagcaga 60 acgccagggg accctcacct gggcgcgccg gggcacgggc tttgattgtc ctggggtcgc 120 ggagacccgc gcgcctgccc tgcacgccgg gcggcaacct ttgcagtcgc gttggctgct 180 gcgatcggcc ggcgggtccc tgccgaaggc tcggctgctt ctgtccacct cttacacttc 240 ttcatttatc ggtggatcat ttcgagagtc cgtcttgtaa atgtttggca ctttgctact 300 ttattgcttc tttctggcga cagttccagc actcgccgag accggcggag aaaggcagct 360 gagcccggag aagagcgaaa tatggggacc cgggctaaaa gcagacgtcg tccttcccgc 420 ccgctatttc tatattcagg cagtggatac atcagggaat aaattcacat cttctccagg 480 cgaaaaggtc ttccaggtga aagtctcagc accagaggag caattcacta gagttggagt 540 ccaggtttta gaccgaaaag atgggtcctt catagtaaga tacagaatgt atgcaagcta 600 caaaaatctg aaggtggaaa ttaaattcca agggcaacat gtggccaaat ccccatatat 660 tttaaaaggg ccggtttacc atgagaactg tgactgtcct ctgcaagata gtgcagcctg 720 gctacgggag atgaactgcc ctgaaaccat tgctcagatt cagagagatc tggcacattt 780 ccctgctgtg gatccagaaa agattgcagt agaaatccca aaaagatttg gacagaggca 840 gagcctatgt cactacacct taaaggataa caaggtttat atcaagactc atggtgaaca 900 tgtaggtttt agaattttca tggatgccat actactttct ttgactagaa aggtgaagat 960 gccagatgtg gagctctttg ttaatttggg agactggcct ttggaaaaaa agaaatccaa 1020 ttcaaacatc catccgatct tttcctggtg tggctccaca gattccaagg atatcgtgat 1080 gcctacgtac gatttgactg attctgttct ggaaaccatg ggccgggtaa gtctggatat 1140 gatgtccgtg caagctaaca cgggtcctcc ctgggaaagc aaaaattcca ctgccgtctg 1200 gagagggcga gacagccgca aagagagact cgagctggtt aaactcagta gaaaacaccc 1260 agaactcata gacgctgctt tcaccaactt tttcttcttt aaacaggatg aaaacctgta 1320 tggtcccatt gtgaaacata tttcattttt tgatttcttc aagcataagt atcaaataaa 1380 tatcgatggc actgtagcag cttatcgcct gccatatttg ctagttggtg acagtgttgt 1440 gctgaagcag gattccatct actatgaaca tttttacaat gagctgcagc cctggaaaca 1500 ctacattcca gttaagagca acctgagcga tctgctagaa aaacttaaat gggcgaaaga 1560 tcacgatgaa gaggccaaaa agatagcaaa agcaggacaa gaatttgcaa gaaataatct 1620 catgggcgat gacatattct gttattattt caaactyttc caggaatatg ccaatttaca 1680 agtgagtgag ccccaaatcc gagagggcat gamaagggta gaaccacaga ctgaggacga 1740 ectcttccst tgtacttgcc ataggaaaaa gaccaaagat gaactstgat atgcaaaata 1800 acttctatta gaataatggt gctctgaaga ctcttcttaa ctaaaaagaa gaattttttt 1860 aagtattaat tccatggaca atataaaatc tgtgtgattg tttgcagtat gaagacacat 1920 ttctacttat gcagtattct catgactgta ctttaaagta catttttaga attttataat 1980 aaaaccacct ttattttaaa aaaaaaaaaa as 2012 <210> 20 <211> 502 <212> PRT

<213> Homo Sapiens-<400> 20 Met Phe Gly Thr Leu Leu Leu Tyr Cys Phe Phe Leu Ala Thr Val Pro Ala Leu Ala Glu Thr Gly Gly Glu Arg Gln Leu Ser Pro Glu Lys Ser Glu Ile Trp G1y Pro Gly Leu Lys Ala Asp Val Val Leu Pro Ala Arg Tyr Phe Tyr Ile Gln Ala Val Asp Thr Ser Gly Asn Lys Phe Thr Ser Ser Pro Gly Glu Lys Val Phe Gln Val Lys Val Ser Ala Pro Glu Glu Gln Phe Thr Arg Val Gly Val Gln Val Leu Asp Arg Lys Asp Gly Ser Phe Ile Val Arg Tyr Arg Met Tyr Ala Ser Tyr Lys Asn Leu Lys Val Glu Ile Lys Phe Gln Gly Gln His Val Ala Lys Ser Pro Tyr Ile Leu Lys Gly Pro Val Tyr His Glu Asn Cys Asp Cys Pro Leu Gln Asp Ser Ala Ala Trp Leu Arg Glu Met Asn Cys Pro Glu Thr Ile Ala Gln Ile Gln Arg Asp Leu Ala His Phe Pro Ala Val Asp Pro Glu Lys Ile Ala Val Glu Ile Pro Lys Arg Phe Gly Gln Arg Gln Ser Leu Cys His Tyr Thr Leu Lys Asp Asn Lys Val Tyr Ile Lys Thr His Gly Glu His Val Gly Phe Arg Ile Phe Met Asp Ala Ile Leu Leu Ser Leu Thr Arg Lys Val Lys Met Pro Asp Val Glu Leu Phe Val Asn Leu Gly Asp Trp Pro Leu Glu Lys Lys Lys Ser Asn Ser Asn Ile His Pro Ile Phe Ser Trp Cys Gly Ser Thr Asp Ser Lys Asp Ile Val Met Pro Thr Tyr Asp Leu -Thr Asp Ser Val Leu Glu Thr.Met Gly Arg Val Ser Leu Asp Met Met Ser Val Gln Ala Asn Thr Gly Pro Pro Trp Glu Ser Lys Asn Ser Thr Ala Val Trp Arg Gly Arg Asp Ser Arg Lys Glu Arg Leu Glu Leu Val ~i Lys Leu Ser Arg Lys His Pro Glu Leu Ile Asp Ala Ala Phe_ Thr Asn Phe Phe Phe Phe Lys Gln Asp Glu Asn Leu Tyr Gly Pro Ile Val Lys His Ile Ser Phe Phe Asp Phe Phe Lys His Lys Tyr Gln Ile Asn Ile Asp Gly Thr Val Ala Ala Tyr Arg Leu Pro Tyr Leu Leu Val Gly Asp Ser Val Val Leu Lys Gln Asp Ser Ile Tyr Tyr Glu His Phe Tyr Asn Glu Leu Gln Pro Trp Lys His Tyr Ile Pro Val Lys Ser Asn Leu Ser Asp Leu Leu Glu Lys Leu Lys Trp Ala Lys Asp His Asp Glu Glu Ala Lys Lys Ile Ala Lys Ala Gly Gln Glu Phe Ala Arg Asn Asn Leu Met Gly Asp Asp Ile Phe Cys Tyr Tyr Phe Lys Leu Phe Gln Glu Tyr Ala Asn Leu Gln Val Ser Glu Pro Gln Ile Arg Glu Gly Met Xaa Arg Val Glu Pro Gln Thr Glu Asp Asp Leu Phe Xaa Cys Thr Cys His Arg Lys Lys Thr Lys Asp Giu Leu <210> 21 <211> 29 <212> DNA
<213> Homo sapiens <400> 21 gnaagaagag agcaacagcc aggaccaag 29 <210> 22 <211> 29 <212> DNA
<213> Homo sapiens <400> 22 cncaggctag gcactgattc tgctggttc 29 <210> 23 E211> 29 <212> DNA
<213> Homo Sapiens <400> 23 gnagacatga aagttgagca gaaggaaag 29 <210> 24 <211> 29 *rB

i ' <212> DNA - _ <213> HomoSapiens <400> 24 gnggtgcttttgatatccagccatctcta 29 <210> 25 <211> 29 <212> DNA

<213> HomoSapiens <400> 25 cntggaaagaggagcaagaaccaaggcag 29 <210> 26 <211> 29 <212> DNA

<213> HomoSapiens <400> 26 tnggttttgtacgttgtgctcttttcatc 29 <210> 27 <211> 29 <212> DNA

<213> Homosapiens <400> 27 tnatggtctatataactgtcctccttcct 29 <210> 28 <211> 29 <212> DNA

<213> HomoSapiens <400> 28 cnacactgggtctcagatccttctgctga 29 <210> 29 <211> 29 <212> DNA

<213> HomoSapiens <400> 29 gnctccaagaagtccagcaaagacaattg 29 <210> 30 <211> 29 <212> DNA

<213> HomoSapiens <400> 30 antgccaaacatttacaagacggactctc 29

Claims (38)

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1 from nucleotide 864 to nucleotide 1340;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:1 from nucleotide 1 to nucleotide 1175;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bi127_5 deposited under accession number ATCC 98501;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bi127_5 deposited under accession number ATCC 98501;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bi127_5 deposited under accession number ATCC 98501;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone bi127_5 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynudeotide which encodes a species homologue of the protein of (h) or (i) above ; and (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.

3. A host cell transformed with the polynucleotide of claim 2.

4. The host cell of claim 3, wherein said cell is a mammalian cell.

5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:

(a) growing a culture of the host cell of claim 3 in a suitable culture medium; and (b) purifying said protein from the culture.

6. A protein produced according to the process of claim 5.

7. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:2;
(b) the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 104;
(c) fragments of the amino acid sequence of SEQ ID NO:2 comprising eight consecutive amino acids of SEQ ID NO:2; and (d) the amino acid sequence encoded by the cDNA insert of clone bi127_5 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

8. The protein of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

9. The protein of claim 7, wherein said protein comprises the amino acid sequence of SEQ ID NO:2 from amino acid 1 to amino acid 104.

10. A composition comprising the protein of claim 7 and a pharmaceutically acceptable carrier.

11. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:1.

12. An isolated polynucleotide selected from the group consisting of:

(a) - a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:3;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:3 from nucleotide 46 to nucleotide 738;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:3 from nucleotide 346 to nucleotide 738;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:3 from nucleotide 688 to nucleotide 1425;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bl194_2 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bl194_2 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone bl194_2 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone bl194_2 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

13. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:4;

(b) the amino acid sequence of SEQ ID NO:4 from amino acid 1 to amino acid 171;
(c) fragments of the amino acid sequence of SEQ ID NO:4 comprising eight consecutive amino acids of SEQ ID NO:4; and (d) the amino acid sequence encoded by the cDNA insert of clone bl194_2 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

14. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:3.

15. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:5;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:5 from nucleotide 234 to nucleotide 1235;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:5 from nucleotide 291 to nucleotide 1235;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:5 from nucleotide 209 to nucleotide 1050;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cc130_1 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cc130_1 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cc130_1 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cc130_1 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;

(k) - a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

16. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:6;
(h) the amino acid sequence of SEQ ID NO:6 from amino acid 1 to amino acid 272;
(c) fragments of the amino acid sequence of SEQ ID NO:6 comprising eight consecutive amino acids of SEQ ID NO:6; and (d) the amino acid sequence encoded by the cDNA insert of clone cc130_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

17. An isolated gene corresponding to the cDNA sequence of SEQ ID N0:5.

18. An isolated polynucleotide selected from the group consisting of:
(a) a polynudeotide comprising the nucleotide sequence of SEQ ID
NO:7;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:7 from nucleotide 1554 to nucleotide 1784;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:7 from nucleotide 1659 to nucleotide 1784;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:7 from nucleotide 1508 to nucleotide 1865;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ch582_1 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ch582_1 deposited under accession number ATCC 98501;

(g) - a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ch582_1 deposited under accession number ATCC 98501;
(h) - a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ch582_1 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(l) a polynucleotide which encodes a speaes homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

19. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:8;
(b) fragments of the amino acid sequence of SEQ ID NO:8 comprising eight consecutive amino acids of SEQ ID NO:8; and (c) the amino acid sequence encoded by the cDNA insert of clone ch582_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

20. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:7.

21. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:9;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:9 from nucleotide 1375 to nucleotide 1605;

(c) a polynucleotide comprising the nucleotide-sequence of SEQ ID
NO:9 from nucleotide 1107 to nucleotide 1539;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cq294_14 deposited under accession number ATCC 98501;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cq294_14 deposited under accession number ATCC 98501;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cq294_14 deposited under accession number ATCC 98501;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone cq294_14 deposited under accession number ATCC 98501;
(h} a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

22. A protein comprising an amino acid sequence selected from the group consisting of:
(a} the amino acid sequence of SEQ ID NO:10;
(b) the amino acid sequence of SEQ ID NO:10 from amino acid 1 to amino acid 55;
(c) fragments of the amino aad sequence of SEQ ID NO:10 comprising eight consecutive amino acids of SEQ ID NO:10; and (d) the amino acid sequence encoded by the cDNA insert of clone cq294_14 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

23. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:9.

24. An isolated polynucleotide selected from the group consisting of:

(a) - a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11 from nucleotide 66 to nucleotide 1880;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:11 from nucleotide 1 to nucleotide 581;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone dd454_1 deposited under accession number ATCC 98501;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone dd454_1 deposited under accession number ATCC 98501;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone dd454_1 deposited under accession number ATCC 98501;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone dd454_1 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (l) a polynudeotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:12;

(b) the amino acid sequence of SEQ ID NO:12 from amino acid 1 to amino acid 172;
(c) fragments of the amino acid sequence of SEQ ID NO:12 comprising eight consecutive amino acids of SEQ ID NO:12; and (d) the amino acid sequence encoded by the cDNA insert of clone dd454_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

26. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:11.

27. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:13;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:13 from nucleotide 462 to nucleotide 3170;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:13 from nucleotide 1188 to nucleotide 1517;
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone du157_12 deposited under accession number ATCC 98724;
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone du157_12 deposited under accession number ATCC 98724;
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone du157_12 deposited under accession number ATCC 98724;
(g) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone du157_12 deposited under accession number ATCC 98724;
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:14;
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:14;
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

28. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:14;
(b) the amino acid sequence of SEQ ID NO:14 from amino acid 251 to amino acid 352;
(c) fragments of the amino acid sequence of SEQ ID NO:14 comprising eight consecutive amino acids of SEQ ID NO:14; and (d) the amino acid sequence encoded by the cDNA insert of clone du157_12 deposited under accession number ATCC 98724;
the protein being substantially free from other mammalian proteins.

29. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:13.

30. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:15;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:15 from nucleotide 865 to nucleotide 1158;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:15 from nucleotide 1108 to nucleotide 1158;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:15 from nucleotide 1 to nucleotide 764;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone du372_1 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone du372_1 deposited under accession number ATCC 98501;

(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone du372_1 deposited under accession number ATCC 98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone du372_1 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:16;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:16 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:16;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

31. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:16;
(b) the amino acid sequence of SEQ ID NO:16 from amino acid 69 to amino acid 98;
(c) fragments of the amino acid sequence of SEQ ID NO:16 comprising eight consecutive amino acids of SEQ ID NO:16; and (d) the amino acid sequence encoded by the cDNA insert of clone du372_1 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

32. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:15.

33. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:17;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:17 from nucleotide 32 to nucleotide 586;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:17 from nucleotide 92 to nucleotide 586;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:17 from nucleotide 1 to nucleotide 481;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ej90_5 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ej90_5 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ej90_5 deposited under accession number ATCC
98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ej90_5 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:18;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:18;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;
(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

34. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:18;
(b) the amino acid sequence of SEQ ID NO:18 from amino acid 1 to amino acid 150;

(c) fragments of the amino acid sequence of SEQ ID NO:18 comprising eight consecutive amino acids of SEQ ID NO:18; and (d) the amino acid sequence encoded by the cDNA insert of clone ej90_5 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

35. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:17.

36. An isolated polynucleotide selected from the group consisting of:
(a) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:19;
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:19 from nucleotide 281 to nucleotide 1786;
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:19 from nucleotide 332 to nucleotide 1786;
(d) a polynucleotide comprising the nucleotide sequence of SEQ ID
NO:19 from nucleotide 1 to nucleotide 574;
(e) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ic2_6 deposited under accession number ATCC 98501;
(f) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ic2_6 deposited under accession number ATCC 98501;
(g) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ic2_6 deposited under accession number ATCC
98501;
(h) a polynucleotide encoding a mature protein encoded by the cDNA
insert of clone ic2_6 deposited under accession number ATCC 98501;
(i) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:20;
(j) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:20;
(k) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(h) above;

(l) a polynucleotide which encodes a species homologue of the protein of (i) or (j) above ; and (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

37. A protein comprising an amino acid sequence selected from the group consisting of:
(a) the amino acid sequence of SEQ ID NO:20;
(b) the amino acid sequence of SEQ ID NO:20 from amino acid 1 to amino acid 98;
(c) fragments of the amino acid sequence of SEQ ID NO:20 comprising eight consecutive amino acids of SEQ ID NO:20; and (d) the amino acid sequence encoded by the cDNA insert of clone ic2_6 deposited under accession number ATCC 98501;
the protein being substantially free from other mammalian proteins.

38. An isolated gene corresponding to the cDNA sequence of SEQ ID NO:19.